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Abstract 
 
Dysregulation of innate immune signalling pathways has been implicated in a host of 
chronic inflammatory disorders including Multiple Sclerosis, Crohn’s Disease and 
Rheumatoid Arthritis. As a result, it is critical that there are tight regulatory mechanisms in 
place to rigidly control such signalling pathways. The IL-17 family of cytokines, which 
comprises six members in mammals, are potent mediators of inflammation. Produced 
primarily by CD4
+ 
T helper 17 (Th17) cells, they signal through IL-17 receptor family 
complexes and protect the host against bacterial infection. Each member of the IL-17R family 
is composed of an extracellular Fibronectin III-like (FnIII) domain, a single transmembrane 
domain and an intracellular similar expression to FGF genes (SEF)/IL-17R (SEFIR) domain, 
which is crucial for IL-17 signalling and is homologous to the TIR domains of Toll-Like 
Receptors (TLRs).  
Here, we describe a role for IL-17RD, also known as Sef, the remaining orphan 
receptor of the family, as a functional regulator of innate immune signalling. Small 
interfering RNAs (siRNAs) and short hairpin RNAs (shRNAs) were used to suppress 
endogenous expression of IL-17RD leading to enhanced activation of NF-κB and NF-κB  
responsive genes by TLR ligands such as Lipopolysaccharide (LPS) and 
poyinosinic:polycytidylic acid (Poly I:C). We demonstrate that IL-17RD can differentially 
regulate the various pathways employed by IL-17A. Neutrophil recruitment, in response to in 
vivo administration of IL-17A, is abolished in IL-17RD-deficient mice, correlating with 
reduced IL-17A-induced activation of p38 MAPK and expression of the neutrophil 
chemokine MIP-2. In contrast, IL-17RD deficiency results in enhanced IL-17A-induced 
activation of NF-κB and IL-6 and KC expression. IL-17RD disrupts the interaction of Act1 
and TRAF6 causing differential regulation of NF-κB and p38 MAPK signalling pathways. 
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Chapter 1 
 
 
General Introduction 
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1.1 The mammalian immune system 
 
The immune system is the body’s defence against invasion and colonisation by foreign 
material. Mammals possess a complex immune system consisting of two branches which 
function interdependently to stave off infection. These arms comprise of the innate and 
adaptive immune systems. The latter, which initially arose in gnathostomates or jawed 
vertebrates, encompasses specialised cells and processes which help relieve disease. The 
adaptive immune system is associated with immunological memory and specific tailored 
responses to particular pathogens. Its functions are performed by a specialised type of white 
blood cell called lymphocytes. T cells and B cells are the major types of lymphocytes. These 
cells have the ability to distinguish a wide selection of pathogens through their cell surface 
receptors. Each of these cells has a unique antigen receptor generated by somatic gene 
rearrangement which occurs during lymphocyte development. This process leads to a vast 
range or repertoire of receptors specific to each antigen (Janeway et al. 2005). 
 B cells and T cells are derived from hematopoietic stem cells. T cells are so called due to 
their development in the thymus while the B cell is named after the Bursa of Fabricius, an 
organ in birds in which their B cells mature. B cells are intimately involved in the humoral 
immune response, whereas T cells play a central role in cell-mediated immune responses. 
These lymphocytes circulate the lymphatic system with no effector function and act merely 
as surveillance agents. However, once their specific antigen is recognised they have the 
ability to proliferate and differentiate into effector cells. In addition to this recognition, in 
order for differentiation to occur, co-stimulatory molecules of Antigen Presenting Cells 
(APCs)  from the innate immune system must be present (Medzhitov and Janeway. 1997). 
 B cell activation leads to plasma cell differentiation. These terminally differentiated 
cells produce antibodies. Antibodies are secreted proteins which recognise their specific 
foreign antigen. There are 3 main effector mechanisms by which antibodies can contribute to 
immunity. Firstly, in a process known as neutralisation, antibodies prevent the invading 
pathogen from entering the cell to subsequently cause damage by binding to the cell surface 
antigen. Phagocytosis by innate immune cells is triggered by opsonisation or the coating of 
the pathogens by antibody. Antibodies also stimulate activation of the complement system, a 
set of plasma proteins which function together to attack the bacteria which can result in either 
phagocytosis promotion or direct membrane pore creation resulting in pathogen destruction.  
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 T cells are distinguished from other lymphocytes by the presence of a cell surface T 
cell receptor. There exist several subsets of T cell, each with distinct functions. Cytotoxic or 
killer T cells (CD8
+
) do their work by releasing lymphotoxins, which cause cell lysis. Helper 
T cells secrete chemicals called lymphokines that stimulate cytotoxic T cells and B cells to 
grow and divide, attract neutrophils, and enhance the ability of macrophages to engulf and 
destroy microbes. Regulatory T cells are crucial for the maintenance of immunological 
tolerance. Their major role is to shut down T cell-mediated immunity toward the end of an 
immune reaction and to suppress auto-reactive T cells. As effective and specific as the 
adaptive immune system is, unfortunately, it can take anywhere from 4 to 7 days post 
infection for it to respond because of the duration of generation of T cell and B cell receptors, 
clonal selection and expansion. However, the older and more universal innate immune system 
is significantly more instinctive resulting in a rapid response which can halt the spread of 
infection during this time (Janeway et al. 2005)  
 
The innate immune system has two main responsibilities, it acts as the first line of 
defence against invading pathogens and it determines the type of response to be mounted 
against the pathogens. It consists of the cells and mechanisms which protect the host from 
infection in a non-specific manner and thus is different from the adaptive system in that it 
does not confer any long lasting or protective immunity to the host (Janeway et al. 2005). It 
incorporates the action of white blood cells, antimicrobial proteins and the inflammatory 
response. Physical barriers are vital mechanisms of the innate response functioning as they do 
to keep pathogen burden low (Janeway 2001). The skin and mucous membranes are the 
initial anatomical obstacles. Secretions from these membranes are additional defense 
mechanisms. Chemical secretions such as sweat and tears can trap microorganisms, altering 
the environmental pH, which results in an unfavourable environment for the microbes. 
Desquamation of skin epithelium aids the removal of infectious agents that have become 
attached to external surfaces. In the gastrointestinal tract, microbial removal is achieved by 
the rhythmic movement due to peristalsis. Here, gut flora may also play a role by secreting 
toxins or merely competing with the would-be-colonisers for nutrients (Janeway 2001).  
Acute inflammation is initiated by cells already present in the compromised tissues, 
mainly resident macrophages, dendritic cells, Kupffer cells and mastocytes. Chemical factors 
produced during the inflammatory response sensitize pain receptors, cause vasodilation of 
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the blood vessels at the scene, and attract other immune cells (Janeway 2001).
 
Neutrophils are 
one of first cells to arrive at the scene of inflammation where they help phagocytose and 
remove the pathogenic invader (Kovach and Standiford 2012). They also trigger the 
recruitment of other parts of the immune system. Monocytes, macrophage precursor cells, are 
summoned to the site and subsequently differentiate into other macrophages which can 
release antimicrobial peptides and Nitric Oxide (NO). Meanwhile, other types of cells such as 
Mast Cells release histamine and proinflammatory cytokines such as TNF while NK cells kill 
virus infected cells (Liebson 2004). The later stages of the acute response result in the 
clotting of blood vessels which limits the spread of infection and promotes the healing of any 
damaged tissue following the removal of pathogens (Janeway 2001) 
  
1.2 Pattern Recognition Receptors 
 
An integral component of the innate immune system is the existence of germ line 
encoded pattern recognition receptors (PRRs). These PRRs have the ability to recognise a 
wide array of pathogen associated molecular patterns (PAMPs). PAMPs are highly conserved 
microbial motifs (Janeway and Medzhitov 2002). These motifs are not found on host cells 
and thus allow the PRRs to distinguish between self and infectious agents. A requirement of 
these motifs is that that they are highly conserved and necessary for microbial viability so 
that they are not lost from the genetic makeup of microorganisms given the high mutation 
rate during replication. Loss of the PAMP would render the microorganism undetectable. 
PAMPs may also be consistently present within classes of microbes thus enabling a limited 
number of PRRs to detect a vast panoply of microbial infections (Medzhitov 2001).  Flagellin 
is a protein PAMP present in flagellated bacteria while another PAMP, Lipopolysaccharide 
(LPS), is a major component of gram negative bacterial cell walls (Newton and Dixit 2012). 
Double stranded RNA (dsRNA) is utilised by most viruses throughout their lifespan, but 
crucially not mammals, and is recognised by PRRs (Newton and Dixit 2012). Furthermore, 
damage associated molecular patterns (DAMPs) which are associated with cellular 
components released due to injury are also detected by PRRs. For example, ATP and 
adenosine are released in high concentrations after necrotic cell death and thus may function 
as DAMPs (Goh and Midwood 2012). PAMPs are found on all bacteria, viruses, fungi and 
protozoa. PRRs can be divided into three categories; secreted proteins, transmembrane 
receptors and intracellular receptors (Medzhitov and Janeway. 1997). 
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1.2.1 Secreted PRRs 
 
Secreted PRRs are those which do not remain associated with the cell that produces 
them and are free to circulate through the blood (Medzhitov and Janeway. 1997). These types 
of PRRs include complement receptors, collectins, ficolins and pentraxins which are all 
secreted proteins (Roeder et al 2004). The mannose binding lectin (MBL) is one such 
receptor which is present as a free protein in blood plasma. MBL is a vital PRR of the innate 
immune response which can bind to a particular orientation of sugar residues on bacteria thus 
initiating the lectin pathway of complement activation (Takahashi 2011). 
 
1.2.2 Transmembrane PRRs 
 
The next set of receptors are the membrane bound PRRs. These include the C type 
Lectin Receptors (CLRs) which are a large family of carbohydrate recognition domain (CRD) 
containing proteins. One such CLR, Dectin-1, is responsible for the recognition of β-glucan, a 
polysaccharide, which is a major component of the fungal cell wall (Janeway and Medzhitov. 
2002). One of the most important families of transmembrane PRRs to have emerged within 
the last 20 years has been the Toll-like receptors (TLRs). While they recognise a wide variety 
of PAMPs, their expression is very much cell-type specific in that they are primarily 
expressed on cells of the innate immune response including macrophages and Dendritic Cells 
(DCs) (Iwasaki and Medzhitov 2010). TLRs recognise PAMPs present on extracellular or 
endosomal surface pathogens. TLRs are categorised into several groups based on the PAMPs 
they recognise. TLR 1, 2, 4 and 6 recognize lipids. TLR4 recognises LPS, a major component of 
the bacterial cell wall, which is responsible for septic shock (Chow et al. 1999). TLR 2 can 
heterodimerise with TLR1, 6 and non- TLRs such as CD36 to detect a range of PAMPs such as 
peptidoglycan, lipopeptides and fungal zymosan. TLR1/2 and TLR 2/6 can discriminate between 
triacyl- and diacyl-lipopeptide (Farhat et al. 2008). TLR 5 and TLR 11 recognise protein ligands. 
TLR5, expressed highly in intestinal lamina propria cells, detects bacterial flagellin (Hayashi et 
al. 2001). The endosomal TLRs 3, 7, 8 and 9 detect microbial nucleic acids (Alexopoulou et al. 
2001; Diebold et al. 2004; Bauer et al. 2001). Post PAMP recognition, TLRs then initiate 
downstream signaling cascades which result in activation of transcription factors such as nuclear 
factor (NF)-κB and the interferon regulatory factor (IRF) family of transcription factors (Iwaski 
and Medzhitov. 2004). This leads to the induction of inflammatory cytokine genes such as TNF, 
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IL-6, IL-1β and IL-12, anti-viral interferons (IFNs) and co stimulatory molecules on DCs which 
are critical for modulation of the adaptive immune response (Medzhitov et al. 1997). 
 
1.2.3  Cytoplasmic PRRs 
 
 There are two main families of cytoplasmic PRRs which have been extensively 
characterised. The NOD-like receptor (NLR) is a large family of intracellular sensor of stress 
and microbial degradation products (Saleh 2011). The NLRs consist of 3 domains. The C 
terminus has, in a similar fashion to TLRs, a LRR which mediates ligand binding. 
Additionally, there is a central nucleotide-binding oligomerisation domain (NOD) and an N 
terminal effector domain which are required for propagation of the downstream signal (Saleh 
et al 2011). The NODs contain caspase recruiting (CARD) domains; NALPs have pyrin 
domains while NAIP has baculoviral repeat (BIR) domains (Ting et al. 2006). While some 
NLR signal transduction results in the activation of NF-κB, others form a multiprotein 
complex called the inflammasome (Martinon et al 2002). Inflammasomes ultimately lead to 
the production of key cytokines such as IL-1β and IL-18 by the cleavage of pro-IL-1β and 
pro-IL-18 by caspase-1. This pro-IL-1β is generally produced by TLR signalling highlighting 
a cooperative role between two different sets of PRRs (Creagh and O’Neill, 2006). Another 
family of cytoplasmic PRRs are the retinoic acid-inducible gene I (RIG-I)-like receptors 
(RLR), such as RIG-I and melanoma differentiation factor 5 (MDA5). RLR members are 
expressed in most cell types and detect viral RNA through their helicase domain and signal 
through their caspase recruitment domains. Both RIG-I and Mda5 recruit a CARD containing 
protein IFN-β promoter stimulator 1 (IPS-1) or mitochondrial anti-viral signalling (MAVS) 
via CARD-CARD interactions (Kawai et al. 2005; Meylan et al. 2005; Seth et al. 2005; Xu et 
al. 2005) MAVS displays two CARD domains that are important for initiating signalling 
downstream and for mitochondrial localisation. Signalling via IPS-1 leads to activation of 
IRF3 and NF-κB and consequently interferon production (Saleh 2011).  
  
1.3  Toll-like Receptors 
 
Toll, a gene first discovered in Drosophila melanogaster, is required for dorsoventral 
axis formation in fruit fly larvae and was subsequently discovered to have a role in antifungal 
immunity in Drosophila adults (Lemaitre et al. 1996). It was noted that the Toll pathway 
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shared similarity with the NF-κB pathway in mammals and this led to the discovery of the 
human Toll receptor, now known as TLR4 (Medzhitov et al. 1997). Since this initial 
breakthrough, 13 murine and 11 human TLRs have been identified each with a different 
specificity for the various PAMPs. TLRs have emerged as an important family of Type I 
transmembrane PRRs and are characterised by extracellular leucine-rich repeats that are 
responsible for PAMP-binding and a highly conserved intracellular Toll/IL-1R (TIR) domain 
that is shared with the IL-1 receptor family (Medzhitov et al. 1997; Rock et al. 1998). 
Interestingly, research has shown that the IL-1R family uses many of the same signalling 
intermediates as TLRs although TLRs do not possess the extracellular Immunoglobulin (Ig)-
like domains which control ligand recognition in the IL-1R family   (Martin and Wesche, 
2002). Upon ligand binding, TLRs can either homo- or heterodimerise with other TLRs in 
order to be able to attract downstream TIR domain containing adaptor proteins responsible 
for signal propagation. Myeloid Differentiation factor 88 (MyD88) is a TIR domain 
containing adaptor protein which transduces the signal from all TLRs except TLR3. It also 
functions as a key mediator for the IL-1 and IL-18 receptors (Adachi et al. 1998; Janssens 
and Beyaert 2002). The recruitment of MyD88 to the TLR results in the downstream 
activation of the transcription factors NF-κB and AP-1, which regulate the expression of pro-
inflammatory gene expression. TLR2 and TLR 4 require a bridging adaptor, MyD88 adaptor 
like (Mal) to link MyD88 to the receptor. TIR domain- containing adaptor inducing IFN- β 
(TRIF) is utilised by TLR3 and TLR4 leading to subsequent activation of NF-κB and IRFs 
(Jiang et al. 2004). TLR4 needs an additional adaptor protein TRIF-related adaptor molecule 
(TRAM) to act as a bridge between the receptor and TRIF (Oshiumi et al. 2003). 
 
1.3.1  TLR1, 2, 6 and 10 
 
TLR2 has the greatest repertoire of ligands. It is involved in recognition of 
lipoarabinomannan from mycobacteria (Underhill et al. 1999) glycoinositolphospholipids 
from protozoa (Campos et al. 2001) and glycolipids from spirochetes (Opitz et al. 2001). It 
was shown that TLR1 and TLR6 can form heterodimers with TLR2 when TLR2 dominant 
negative forms of both blocked TLR2 signalling (Ozinsky et al. 2000; Hajjar et al. 2001). 
TLR2 and TLR6 heterodimers are also crucial for recognising yeast zymosan, a cell wall 
component of Saccharomyces cerevisae. A C-type lectin; Dectin-1 can collaborate with 
TLR2 and TLR6 to mediate independent but cooperative signalling in response to zymosan. 
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Dectin-1 triggers release of reactive oxygen species (ROS) and promotes phagocytosis, while 
the TLR2-TLR6 heterodimer triggers NF-κB signalling leading to the production of 
inflammatory cytokines, such as IL-12 whose production is enhanced by Dectin-1 (Gantner et 
al. 2003).  
 
1.3.2 TLR3 
 
TLR3 is expressed on the endosomes of immune cells such as macrophages, NK cells 
and mDCs and recognises viral nucleic acids (Kumar et al. 2009). This is a strategic location 
for viral detection as these TLRs can detect nucleic acids released by bacteria and viruses that 
are internalised for delivery to the endosome. TLR3 is essential for recognising viral dsRNA 
which is the genetic information of some viruses. dsRNA is also produced by most other 
viruses at some point in their replication process. It can also recognise the stable synthetic 
dsRNA mimic polyriboinosinic : polyribocytidylic acid (Poly I:C) (Tabeta et al. 2004). TLR3 
has been shown to have a protective role against viral infection highlighted by increased 
susceptibility to cytomegalovirus in TLR3 knockout mice (Tabeta et al. 2004). In contrast, it 
has been shown to increase disease pathogenesis in response to West Nile Virus (WNV) 
(Wang et al. 2004).  
 
1.3.4  TLR4 
 
Situated in the outer membrane of Gram negative bacteria, the endotoxin LPS consists 
of a Lipid A part and a core oligosaccharide with polysaccharide side chains. The most 
conserved region of the lipoglycan, Lipid A, is the region of LPS detected by TLR4. TLR4 is 
not sufficient in itself for LPS recognition. LPS is initially bound in serum by LPS-binding 
protein (LBP), which delivers the ligand to a membrane protein, CD14. CD14 exists as both a 
soluble form and a GPI-linked outer membrane protein and serves as a receptor for LPS 
(Aderem and Ulevitch. 2000). CD14 associates with TLR4 and an extracellular accessory 
protein MD2. Each member of this triumvirate is indispensible for ligand recognition and 
subsequent signalling (Shimazu et al. 1999). In addition to LPS, TLR4 has also been 
implicated in the recognition of a diverse range of other PAMPs. Interestingly, TLR4 has 
been implicated in recognition of viral-derived proteins. It was shown to have the ability to 
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recognise the fusion protein (F protein) of respiratory syntical virus (RSV) (Kurt-Jones et al. 
2000) and the envelope protein from mouse mammary tumor virus (MMTV) (Rassa et al. 
2002). Additionally, TLR4 can prompt an immune response to endogenous molecules. Heat-
shock protein 60 (Hsp60) activates TLR4, serving as a danger signal for the innate immune 
system (Ohashi et al. 2000). Fragments of hyaluronic acid, the extra domain A (EDA) of 
fibronectin and the anti-microbial β-defensin 2 released during inflammation all activate 
TLR4 (Termeer et al. 2002; Okamura et al. 2001; Biragyn et al. 2002). 
 
1.3.5  TLR 5 and TLR11 
 
The primary ligand for TLR5 is flagellin, a protein found in the flagella of gram 
negative bacteria (Hayashi et al 2001). TLR5 is found expressed on a wide variety of immune 
cells including monocytes, dendritic cells, T lymphocytes, natural killer cells and also 
epithelial cells. It has been demonstrated that TLR5 and TLR9 have an effect on each other’s 
signalling. TLR9, primarily found on expressed on plasmacytoid dendritic cells and B 
lymphocytes favours a TH1 response promoting cell mediated immunity (Davis et al 1998). 
However, TLR5 initiates a TH2-like response which favours humoral responses (Marshall et 
al. 2004). It was thus shown that flagellin can inhibit TLR9 mediated cell activation and 
cytokine production. Murine TLR11 shares a similar structure to TLR5. It is found highly 
expressed in the kidney and the bladder. TLR11 knockout mice have been shown to be 
susceptible to uropathogenic bacterial infection (Zhang et al. 2004). There is dose dependent 
NF-κB activation by murine TLR11 in response to profilin, an actin binding protein from the 
protozoan Toxoplasma gondii (Yarovinsky et al. 2005). 
 
1.3.6  TLR7, TLR8 and TLR9 
 
TLR 7 and 8 are involved in viral detection. In TLR7 deficient mice, there is 
abrogated cytokine and Type I interferon production in response to synthetic 
imidazoquinoline-like molecules including imiquimod and resiquimod in addition to 
guanosine analogs such as loxoribine (Hemmi et al. 2002). Human and murine TLR8 share 
significant similarity with TLR7 however only the human homolog responds to resiquimod 
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(Jurk et al. 2002). Uridine and guanosine are major components of viral ssRNA but they are 
also found in host nucleic acids. The localisation of TLR7 in endosomal compartments where 
host nucleic acids are usually absent allows for a specific response to viral RNA (Diebold et 
al 2006). However, host nucleic acid may still possess stimulatory activity. The inefficient 
removal of debris from apoptotic cells can result in host nucleic acids activating TLRs 
resulting in autoimmunity (Leadbetter et al. 2002).  
Unmethylated 2’-deoxyribocytidine-phosphate-guanosine (CpG) DNA is detected by 
TLR9 on pDC and B cells in humans. This mechanism is employed to recognise intracellular 
pathogenic DNA of viral or bacterial origin. CpG sites are regions of DNA where there is a 
high frequency of cytosine nucleotides occurring next to guanosine nucleotides and are 
usually unmethylated turning the gene off. While unmethylated CpG DNA is relatively rare 
in mammals (~1%), it is more inherent in bacterial and viral DNA. Consequently, CpG has 
some vital characteristics of a PAMP. It is a property of microorganism cells but not of host 
cells (Medzhitov 2001). It is distinctive to a large number of otherwise unrelated 
microorganisms. Additionally, CpG is highly conserved being essential for the viability of the 
microbe and any mutants lacking the PAMP are unable to survive. In addition to CpG, TLR9 
detects hemezoin from blood feeding parasites such as the Plasmodium spp., the causative 
agent of malaria (Coban et al. 2005). It is a hydrophobic heme polymer produced from the 
digestion of host haemoglobin by the parasites. Serving as a TLR9 agonist, it induces the 
production of inflammatory cytokines in macrophages and DCs.  
 It has been demonstrated that human TLR8 dimerises with both TLR7 and TLR9. 
Additionally, TLR8 ligands have been observed to function as TLR7 and TLR9 antagonists 
(Wang et al 2006). Furthermore, TLR9 interacts with TLR7, antagonising its signalling. This 
interplay exposes a hitherto unknown level of complexity governing TLR signalling 
networks. 
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1.4  TLR signalling 
 
TLR signalling pathways stem from the cytoplasmic TIR domain. There are at least 
four TIR adaptors responsible for transducing the ligand recognition signal. These include 
MyD88, Mal, TRIF and TRAM. These proteins associate with the TLR through homotypic 
TIR-TIR interactions. MyD88 is viewed as a universal adaptor as it is shared by all TLRs 
with the notable exception of TLR3. Consequently, resulting TLR signalling cascades are 
defined by their employment of MyD88 (Takeda and Akira. 2004).  
 
1.4.1  MyD88-dependent signalling 
 
MyD88 is comprised of an N-terminal death domain and an intracellular C-terminal 
TIR domain. Upon ligand binding, a conformational change is induced which allows for 
MyD88 to recruit the IL-1 receptor-associated kinases (IRAKs) to TLRs via the interaction of 
the death domain of both molecules (Wesche et al. 1997; Burns et al. 1998; Medzhitov et al. 
1998). The members of the IRAK serine/threonine kinase family include: IRAK1, IRAK2, 
IRAKM, and IRAK4. However, only IRAK1 and IRAK4 are active kinases (Li et al. 2002). 
IRAKs are activated by phosphorylation. IRAK1 phosphorylation leads to dissociation of the 
IRAKs from the receptor MyD88 complex and subsequent association with TNF receptor-
associated factor 6 (TRAF6) (Qian et al. 2001). TRAF6 is a ubiquitin E3 ligase. It functions 
along with ubiquitin-conjugating enzyme 13 (Ubc13) and Uev1a, a Ubc-like protein, to 
initiate the synthesis of Lys63-linked polyubiquitin chains on target proteins including 
TRAF6 molecules (Wang et al. 2001). The MyD88-IRAK-TRAF6 axis constitutes the basis 
of the MyD88-dependent pathway. These events lead to the activation of the IκB kinase 
(IKK) complex. This multi-protein complex causes phosphorylation of IκB, which sequesters 
the transcription factor NF-κB outside the nucleus. Upon its phosphorylation, IκB is degraded 
which allows NF-κB to enter the nucleus and activate transcription of pro-inflammatory 
cytokine genes (Hayden and Ghosh. 2004). 
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1.4.2  MyD88 independent signalling 
 
As expected, MyD88 deficient macrophages failed to show any activation of NF-κB 
and AP-1 in response to most TLR ligands. However, treatment of these cells with LPS 
resulted in the transcription factor activation albeit with delayed kinetics relative to wild type 
macrophages (Yamamoto et al. 2002). This novel discovery pointed towards a MyD88-
independent signalling pathway.  The key adaptor protein in this pathway is TRIF. TRIF 
interacts directly with TLR3 while TRAM is required to function as a bridging adaptor for 
the association between TRIF and TLR4 (Oshiumi et al. 2003). Once TRIF is recruited to the 
receptor, it subsequently interacts with receptor interacting protein 1 (RIP1). The C-terminus 
of TRIF possesses a RIP homotypic interaction motif (RHIM) and through this RIP-1 is 
allowed to interact. In the absence of RIP-1, TLR3 and TLR4 mediated transcription factor 
activation is abrogated highlighting the requirement of RIP-1 for signal transduction (Meylan 
et al. 2004). The recruitment of RIP-1 and TRAF6 facilitates transforming growth factor-β 
(TGF-β) activating kinase (TAK1) activation which subsequently leads to NF-κB and MAPK 
induction. 
MyD88-independent signalling also leads to the activation of members of the IRF 
family of transcription factors, IRF3 and IRF7. The recruitment of TRIF, to the receptor, 
results in the engagement with TRAF3 (Matsumoto and Seya, 2008). Two non-canonical 
IKKs, inducible IKK (IKKi) and TANK Binding Kinase 1 (TBK1) are subsequently 
recruited. NF-κB-activating kinase (NAK)-associated protein 1 (NAP1) is implicated in 
recruiting these kinases (Sasai et al. 2005). In order for nuclear translocation to occur, both 
IRF3 and IRF7 are phosphorylated at key serine/threonine residues by TBK1 and IKKi 
(Sharma et al. 2003). This phosphorylation promotes dimerisation and transport to the 
nucleus where they interact with their transcriptional co-activators cAMP responsive element 
binding protein (CBP)/p300 (Gauzzi et al. 2010). CBP/p300 acetylates IRF3 homodimers, 
inducing a conformational change which reveals its DNA binding domain (Lin et al. 1999). 
Once inside the nucleus, IRF3 and IRF7 then bind to the promoter regions, activating the 
expression of Type I IFNs (Lin et al. 1999). 
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1.5  Transcription factors 
 
The NF-κB transcription factor is a critical regulator of immunity, stress responses, 
apoptosis and differentiation chiefly due to the vast number of genes it may activate. 
Mammalian NF-κB has five subunits; RelA (p65), Rel B, c-Rel, p100/52 and p105/p50. NF-
κB subunits are located in the cytoplasm, inhibited from entering the nucleus by IκB family 
members (Hayden and Ghosh 2004). Upon IL-1R or TLR activation, degradation of IκB 
occurs, freeing up NF-κB to translocate to the nucleus initiating the induction of pro-
inflammatory genes. Stimulus induced degradation of IκB proteins is promoted via 
phosphorylation by the IκB Kinase (IKK) complex which consists of two catalytically active 
kinases, IKKα and IKKβ, and the regulatory subunit NF-κB essential modulator (NEMO) 
(Hayden and Ghosh 2004). Phosphorylated IκB proteins are targeted for ubiquitination and 
degradation by the 26S proteasome, releasing bound NF-κB dimers to translocate to the 
nucleus.  
There are two main NF-κB-activating pathways which occur in cells. The more 
traditional canonical pathway is initiated by most physiological NF-κB stimuli including the 
signals emanating from cytokine receptors such as the IL-17 receptor and pattern recognition 
receptors such as the Toll-like receptors (Moynagh 2005). It is completely reliant upon the 
functions of IKKβ and NEMO and results in phosphorylation of IκBα and nuclear 
translocation of mainly p65-containing heterodimers. The non-canonical pathway involves 
the processing of p100 to p52 by NIK and IKKα. These kinases phosphorylate p100 which 
results in the cleavage of p100. The resulting protein p52 then forms dimers with RelB to 
mediate gene expression (Moynagh 2005). This pathway of NF-B is only activated by a tiny 
number of ligands, such as CD40 ligand (CD40L), B-cell activating factor belonging to the 
TNF family (BAFF), ligands for the lymphotoxin B receptor (LTbR) and TNF-related weak 
inducer of apoptosis (TWEAK) (Mon Thu and Richmond. 2010). 
TLR signalling also results in the induction of a number of interferon regulatory 
factors (IRFs). There are nine members of the IRF family (IRF1-9) (Moynagh 2005). IRF3 
and IRF7 are key regulators of type I IFN gene expression in response to invading viruses. 
Type I IFNs are a family of cytokines which have pivotal roles in antiviral defence, immune 
activation and cell growth (Goodbourn et al. 2000). Type I IFNs inhibit viral replication and 
stop the spread of infection. This is achieved by IFNs binding to interferon receptors 
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(IFNARs) present on the cell surface on adjacent infected and uninfected cells (Moynagh 
2005). Endoribonucleases are subsequently turned on and these degrade viral nucleic acid.  
IRF3 and IRF7 are activated by TBK1 and IKKi. Interestingly, TBK1 seems to be the 
predominant activator of Type I IFN genes in mouse embryonic fibroblasts (MEFs) (Perry et 
al. 2004). In the MyD88-independent pathway, employed by TLR3/4, TBK1 phosphorylates 
IRF3 and IRF7. However, in plasmacytoid Dendritic Cells (pDCs) IRF7 is activated in a 
TBK1/IKKi-independent manner through the MyD88 alternative pathway (Hoshino et al. 
2006).  
 
1.6  RLR signalling 
 
When a viral infection occurs in mammalian cells, the immune system responds in a 
highly coordinated fashion with the speedy upregulation of antiviral defence proteins, natural 
killer cells, neutralising antibodies and cytotoxic T cells (Janeway 2001). This process is 
regulated by key antiviral signalling molecules which include Type I Interferons (IFNα and 
IFNβ) and the related Type III Interferon (IFNλ) (Chen and Jiang 2012). It is therefore clear 
that the mammalian host cells possess mechanisms that allow for viral detection. One of these 
mechanisms occurs through the RIG-I-like receptor (RLR) family of PRRs in response to 
viral RNA PAMPs generated during the process of virus infection.  
There are 3 members of the RLR family namely the retinoic acid inducible gene 
(RIG-I), melanoma differentiation-associated gene 5 (MDA5) and laboratory of genetics and 
physiology 2 (LGP-2) (Bruns and Horvath 2012). Located in the cytoplasm, these proteins all 
share an integral DExD/H box RNA helicase domain. In addition, RIG-I and MDA5 have 2 
N-terminal CARDs which function in permitting the activated of RIG-I or MDA5 to interact 
with the RLR adaptor protein, mitochondrial antiviral signalling (MAVS; also known as IPS-
1, VISA and Cardif) which subsequently localises to the outer mitochondrial membrane 
(Bruns and Horvath 2012). MAVS transduces the signal to kinases such as TBK1 and IKKε 
which lead to the activation of the transcription factors IRF3, IRF7 and NF-κB (Belgnaoui et 
al 2011). Furthermore, in an a MAVS independent pathway, RIG-I is able to directly turn on 
the inflammasome (Melchjorsen et al. 2010).  
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1.6.1  RLR ligands 
 
RLRs need to be highly discriminatory as they are localised in the cytoplasm where 
there are vast numbers of potentially problematic host RNAs (Loo and Gale 2011). However, 
RLR signalling is only present in virus infected cells. This feat is achieved by RLRs only 
responding to distinctive RNA with unusual patterns. These patterns may include chemical 
modifications of RNA, secondary or tertiary conformations or highly specific sequences (Loo 
and Gale 2011). Interestingly, activation of RLR signalling may be achieved by RNA of viral 
or cellular origin. Early studies demonstrated that RNA transcription in vitro by phage 
polymerase (IVT-RNA) generates a powerful RIG-I ligand (Pichlmair et al. 2008; Hornung 
et al. 2006). These RNAs contain an uncapped 5’ triphosphate (5’PPP) that is essential for 
interferon inducing activity. 5’PPPs are responsible for initiation of binding of RIG-I, 
promotion of its adenosine phosphatase (ATPase) activity and induction of conformational 
changes which permit RIG-I dimerisation and exposure of CARDs for interaction with 
MAVS (Cui et al 2008; Takahasi et al 2008). Host mRNAs are capped at the 5’ end and 
nuclear processing of ribosomal RNA and transfer RNAs removes or alters the 5’PPP groups  
before they get to the cytoplasm. Consequently, it has been demonstrated that viral RNA 
genomes obtained from influenza A or rabies virus particles may trigger RIG-I (Pichlmair et 
al. 2006). These viruses possess a 5’PPP-bearing RNA genome. Additionally, it has been 
shown that enzymatic removal of the 5’PPP stops its ligand activity (Pichlmair et al 2006; 
Hornung et al, 2006). Other viruses, such as Borna disease virus, have a genome that has 
5’monophosphate ends and RNA obtained from such viruses does not possess RIG-I 
stimulating activity (Habjan et al. 2011).  
The RNA genomes of viruses recognised by RIG-I have complementary 5’ and 3’ 
ends and adopt a panhandle conformation. As a result, these provide 2 features detected by 
RIG-I: 5’PPP and base pairing at the 5’ end (Habjan et al. 2011). Other features of RNAs 
which influence RIG-I ligand activity is the inclusion of modified bases such as pseudo-
uridine into IVT-RNA which reduces its stimulatory activity (Hornung et al 2006). The 
hepatitis C virus possesses a sequence motif in the 3’ non-translated  region which along with 
the 5’PPP end is essential for RIG-I activity (Saito et al 2008). 
There are also some RNAs without 5’PPPs which activate RIG-1. For example, 
chemically synthesised dsRNA oligonucleotides and some forms of polyinosinic : 
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polycytidylic acid (Poly I:C) (Takahasi et al 2008; Kato et al 2008). Additionally it has been 
demonstrated that the products of host RNA cleavage by ribonuclease (RNAse L) activate 
RIG-I (Malathi et al 2007). Also, phosphorothioated single stranded DNA oligonucleotides 
have been suggested to act as RIG-I antagonists (Ranjith-Kumar et al 2009). There is 
significantly less known about the ligands which cause MDA5 activation. Transfection of 
Poly I:C inside cells induces MDA5-dependent IFN activation (Tamassia et al 2008). It’s 
therefore believed that MDA5 detects dsRNA produced during infection, especially as 
dsRNA builds up in cells infected with viruses detected by MDA5 (Pichlmair et al 2006; 
Kato et al 2008; Pichlmair et al 2009). A surprising discovery is that RLRs may initiate IFN 
induction in response to cytoplasmic DNA. When DNA viruses infect cells, some DNA can 
be sent to the cytoplasm. This is mimicked in vitro by transfecting a DNA polymer poly dA: 
dT into cells. However, poly dA: dT is not able to be detected directly by RLRs. Cytosolic 
RNA polymerase III transcribes it into uncapped RNA which may then lead to RIG-I 
activation (Ablasser et al 2009; Chiu et al 2009). This is the pathway thought to lead to 
induction of interferons during infection with the bacterium Legionella pneumophilia and 
DNA viruses such as adenovirus, herpes simplex and Epstein Barr virus while Vaccinia virus 
is believed to produce an RNA agonist for MDA5 (Pichlmair et al 2009; Chiu et al 2009). 
 
 
1.7  IL-17 Signalling 
 
TLRs can trigger inflammatory responses but also there is a lot of interest in effector 
cytokines and their inflammatory effects especially in inflammatory diseases. Interleukin-17 
(IL-17 or IL-17A) is a key effector cytokine which can be produced as a result of TLR-
induced NF-κB. IL-17 was initially identified as a transcript from a rodent T-cell hybridoma 
(Rouvier et al. 1993). It is the founding member of a group of cytokines called the IL-17 
family. The IL-17 family share homology in amino acid sequences showing highly conserved 
cysteine residues which are important for their conformation (Hymowitz et al 2001). To date, 
there have been 6 members identified, Il-17A-F (Yao et al 1995; Li et al. 2000; Starnes et al 
2002). Although this cytokine serves as a key player in host defence during infection, 
dysregulated expression of IL-17 is implicated in a whole host of inflammatory pathologies 
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such as experimental autoimmune encephalitis (EAE) and collagen induced arthritis (CIA) 
and cancer (Ouyang et al 2008; Dong 2008). Whereas the signature cytokines involved in the 
TH1 and TH2 cell lineages initiate the  JAK–STAT pathway, the IL-17-family cytokines 
induce signalling through a novel ACT1-dependent pathway, resulting in the activation of 
pro-inflammatory factors such as NF-κB that are usually associated with innate immune 
signalling (Gaffen 2011). Consequently, the properties of the IL-17 signalling family lend 
itself to being a mediator between the innate and adaptive immune system.  
 
1.7.1  IL-17 Cytokine family 
 
IL-17A, the hallmark cytokine of the IL-17 family, is secreted by cells of the activated 
immune system, including TH17 cells, γδ T cells and natural killer cells. Human IL-17A is a 
21kDA glycoprotein with 155 amino acids and 63% amino acid homology with murine 1L-
17A (Rouvier et al. 1993). It is a pleiotropic cytokine that exerts its function on numerous 
cell types augmenting the production of pro-inflammatory molecules. IL-17A coordinates 
tissue inflammation and mobilizes neutrophils by stimulating the production of cytokines and 
chemokines, including IL-6, KC and MIP-2 in mice and IL-8 and GRO family members in 
humans, antimicrobial peptides such as defensins and s100 proteins and matrix 
metalloproteinases including MMP9 (Iyoda, M. et al 2010). IL-17A expression is therefore 
tightly regulated. IL-17F shares the highest similarity with IL-17A; in fact IL-17A and IL-
17F can form heterodimers and perform similar functions to IL-17A and IL-17F homodimers 
(Chang and Dong 2009). However, IL-17F can play a distinctive role in some circumstances 
such as during allergic inflammation in the lungs and intestinal inflammation in vivo (Hizawa 
et al. 2006; Yang et al 2008; Ishigame et al. 2009). A striking feature of IL-17A, IL-17F and 
IL-17A/F is their modest signalling activity. Nevertheless, they display great synergy, with 
TNF, LTα, IFNγ and IL-1β (Gaffen, 2009). Although the mechanisms involved are not 
clearly understood, a significant element is the cooperative enhancement of mRNA stability 
of certain IL-17 target genes. For example, IL-6 and CXCL1 are both induced weakly at the 
transcriptional level by IL-17 alone, but their transcript half-life is enhanced dramatically by 
a combination of TNFα and IL-17. IL-17E (IL-25) shares the least homology with IL-17 A. It 
is responsible for facilitation of TH2 cell mediated immune responses, where it has a role in 
allergic disease and defence against helminthes (Barlow and McKenzie 2009). A range of 
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cellular sources of IL-25 have been identified namely epithelial cells, eosinophils, mast cells 
and basophils.  The roles of the remaining cytokines IL-17B, IL-17C and IL-17D are as of yet 
not fully elucidated.  
 
1.7.2 IL-17 Receptor Family 
  
The IL-17 receptor family consists of five members (IL-17RA, RB, RC, RD and RE) 
and each shares significant homology to the first discovered member, IL-17RA (Kolls et al 
2004; Moseley et al. 2003; Aggarwal and Gurney 2002). IL-17 signalling is abrogated in IL-
17R (IL-17RA) knockout mice and furthermore soluble IL-17RA or even anti-IL-17RA 
antibodies have been shown to inhibit the activity of IL-17 in human epithelial cells 
highlighting the requirement of IL-17R for IL-17 signalling (Toy et al 2006; Ye et al 2001; 
McAllister et al 2005). IL-17RA is constitutively expressed on a wide variety of tissues 
whereas IL-17RC is mainly expressed in non-hematopoietic tissues. Despite this ubiquitous 
expression, IL-17RA is dynamically regulated. Treatment with IL-15 and IL-21 increase 
expression of IL-17RA in CD8+ T cells
 
and phosphoinositide 3-kinase (PI3K) inhibits IL-
17RA expression in T cells (Lindeman et al 2008). Interestingly, a major disparity between 
IL-17RC and IL-17RA is that IL-17RC is found expressed as numerous different isoforms 
with approximately 11 splice variants (Haudenschild et al 2002). IL-17A, IL-17F and IL-
17A–IL-17F all signal through the same receptor subunits, IL-17RA and IL-17RC, which 
together form a heteromeric complex (Haudenschild et al 2002) . Another IL-17 receptor, IL-
17RB, has been identified as the receptor for IL-25 (IL-17E). Ligation of IL-15 with IL-17RB 
results in the major tissue infiltration of eosinophils and upregulation of Th2-related 
molecules such as the production of IL-4, IL-5 and IL-13. Also, in lung epithelial cells there 
is increased Th2 cytokine and mucus production resulting in impaired clearance of parasitic 
helminthes in IL-25 knockout mice (Fallon et al 2006). Detailed bioinformatic analysis has 
shown that members of the IL-17R family all possess a “similar expression to FGF/IL-17R” 
(SEFIR) domain. In actual fact, this SEFIR domain bears a striking resemblance to the 
functional TIR domain within the TLR family.  
In addition to the SEFIR domain, all receptor subunits contain an extracellular 
fibronectin III-like domain (Novatchkova et al 2003). IL-17 signals through the IL-17R 
complex to activate MAPK, NF-κB, phosphoinositide-3-kinase (PI3k)-Akt and 
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CCAAT/enhancer binding protein (C/EBP) (Gaffen 2011). In addition to this, IL-17R signal 
transduction shares certain similarities with TLR signaling in that they both employ the 
ubiquitin E3 ligase, TRAF6. However, while there are certain similarities between the 
biological functions of IL-1 signalling, IL-17 signalling does not require TIR domain 
containing adaptors such as MyD88 or TRIF or downstream IL-1 signalling components such 
as IRAK 4 (Gaffen 2011). In fact, a novel adaptor protein, Act1 (transcription factor NF-κB 
activator 1) has been shown to bind to IL-17RA, initiating TRAF6 recruitment allowing for 
the IL-17 signal transduction to occur (Gaffen 2011).  
 
1.7.3  IL-17 signal transduction 
 
As previously alluded to, IL-17A signaling culminates in activation of NF-κB and 
MAP kinases through IL-17RA. However, in TRAF6 knockout mouse embryonic fibroblast 
(MEFs) there is a loss of NF-κB and MAPK activation as well as IL-6 production 
(Schwandner et al. 2000). Furthermore, TRAF6 has been shown to immunoprecipitate with 
IL-17RA when both proteins are overexpressed. As TRAF6 is essential in IL-17RA 
signaling, this suggests a shared similarity with TLR/IL-1R. It has consequently been 
proposed that IL-17R family belongs to a larger group of proteins called similar expression to 
fibroblast growth factor and IL-17R; Toll-IL-1R (STIR). However, IL-17RA does not have a 
TRAF6 binding site, which highlights the need for an adaptor protein which would mediate 
TRAF6 recruitment. One such protein is Act1 (Gaffen 2011).  
Act1 is a cytoplasmic SEFIR domain containing adaptor protein employed by the IL-
17R family for activation of NF-κB and other signals (Shen and Gaffen 2008). Initially 
discovered by a yeast-two hybrid screen based on its interaction with IKKγ, it was found to 
be a negative regulator of CD40 and BAFF-mediated B cell signaling (Wu et al 2012). Act1 
interacts directly with the cytoplasmic domain of IL-17RA. In Act1 knockout cells, IL-17 
signalling is abrogated which highlights the requirement of the adaptor (Qian et al 2008).  
Also, Act-1 deficient mice display less inflammatory disease in autoimmune 
encephalomyelitis and dextran sodium sulfate-induced colitis (Qian et al 2008). As IL-17F 
signaling needs IL-17RA, IL-17F signaling is also lost in Act-1 knockout cells. Furthermore, 
Act1 has been shown to associate with IL-17RC and the interaction increases on IL-17A 
treatment (Yang et al 2008; Ho et al 2010). The SEFIR domain of IL-17RA is necessary for 
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the homotypic interaction with Act1. SEFIR and the TIR-like loop (TILL) domains of IL-
17RA are needed for NF-κB and MAPK induction. The TILL motif has also been declared to 
confer structural integrity to the IL-17RA while an extended area beyond the SEFIR and 
TILL is also implicated in signal propagation (Gaffen 2009). Act1 is also implicated in IL-
17RB signaling. The deletion of the SEFIR domain of Act1 and/or of IL-17RB abolished the 
interaction thus leading to reduced levels of gene expression (Gaffen et al 2009). Recently, a 
novel TRAF6-independent IL-17 mRNA stability signaling pathway has been identified. 
Here, IL-17 promotes interactions among Act1, TRAF2 or TRAF5, and the multifunctional 
RNA-splicing regulatory factor SF2 (ASF) which is a vital component of the splicing process 
(Sun et al 2011). 
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1.8  IL-17RD regulates immune signalling pathways 
 
Immune signalling pathways require tight control as it is clear that dysregulated 
signalling can lead to a whole host of quite serious chronic inflammatory disorders such as 
Inflammatory Bowel Disease, Multiple Sclerosis and Rheumatoid Arthritis. This thesis 
describes a role for a novel regulator of TLR, RIG-I and IL-17 signalling.  
IL-17RD is an orphan receptor from the IL-17 receptor family (Moseley et al. 2003).  
While the immunomodulatory effects of other IL-17 receptors have been identified, the role 
of IL17-RD remains unclear. IL-17RD is also called similar expression to FGF genes (Sef) as 
it shows the same expression patterns in zebrafish embryos as Fibroblast Growth Factor 
genes and it is also a part of the same expression group as fgf8 and sprout. Sef was initially 
characterised as a negative regulator of FGF signalling (Furthauer et al. 2002; Tsang et al. 
2002). Fibroblast growth factors are secreted proteins which function by activating specific 
tyrosine kinases receptors, the FGF receptors which transmit the signal by activating different 
pathways including the Ras/MAP kinase and the phospholipase-C gamma pathways. FGFs 
are important in regulating many developmental processes including patterning, 
morphogenesis, differentiation, cell proliferation or migration (Goldfarb 1996). Different 
targets have been revealed for IL-17RD in FGF signalling. IL-17RD inhibits at the receptor 
level but also downstream at the level of MEK (Furthauer et al. 2002; Kovalenko et al. 2003; 
Tsang et al. 2002; Xiong et al. 2003). IL-17RD also interferes with the dissociation of ERK 
from MEK, impeding the translocation of ERK to the nucleus (Torii et al. 2004).  
 
A number of studies in the past number of years have highlighted IL-17RD’s role in 
many cancers. For example, loss of IL-17RD expression is associated with high grade and 
metastatic prostate cancer and IL-17RD inhibits fibroblast growth factor-induced 
tumourigenic behaviour in prostate cancer cells and is downregulated in aggressive clinical 
disease (Darby et al 2006; Darby et al 2009). Additionally, IL-17RD has been shown to 
reduce the proliferation of endometrial adenocarcinoma cells via inhibiting FGF 2-mediated 
MAPK/ERK signalling pathway (Zhang et al 2011). It has also been implicated as a negative 
regulator of fiber cell differentiation in the ocular lens (Newitt et al 2010). There has been no 
reported physiological role for IL-17RD in IL-17 signalling, apart from a study in which 
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overexpressed IL-17RD was shown to co-operate with IL-17RA (Rong et al. 2009). While 
IL-17RD shares a lot of similarity with the IL-17 receptor family, it also contains a partial 
TIR domain, consisting of boxes 1 and 2 and thus it is part of a larger STIR domain 
superfamily, the name deriving from both SEFIR and TIR domains which have been shown 
to be similar in both length and structure (Novatchkova et al 2003). Consequently, the study 
of IL-17RD’s role in various immune signaling pathways was considered worthy of 
investigation 
 
1.9 Project Aims 
 
 The overall aims of this project were to: 
 1) Explore a molecular and physiological  role for IL-17RD in TLR signalling 
 2) Investigate a role for IL-17RD in other innate immune signalling pathways 
 3) Probe the molecular basis of the role(s) of  IL-17RD in innate immunity.  
 
 
 
 
 
0 
  
 
 
 
Chapter 2 
 
 
 
 
Materials and Methods 
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2.1 Materials 
2.1.1 Reagents 
Reagent        Supplier 
Agar         Sigma 
Agarose        Promega 
Agarose, low melting point      Sigma 
Alexa488        Invitrogen 
Alexa594       Invitrogen 
Ampicillin        Sigma 
Antibodies (monoclonal) against - 
β-Actin        Sigma 
FLAG M2        Sigma 
HA.11        Covance 
Myc-Tag (9B11)       Cell Signaling 
Myc-Tag (71D10)       Cell Signaling 
Antibodies (polyclonal) against - 
ERK1/2        Cell Signaling 
Phospho-ERK1/2       Cell Signaling 
JNK         Cell Signaling 
Phospho-JNK        Cell Signaling 
IRF3         Cell Signaling 
Phospho-IRF-3       Cell Signaling 
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IκBα         Santa Cruz 
Phospho-serine       Abcam 
p38         Cell Signaling 
phospho-p38        Cell Signaling 
p65 (C-20)       Santa Cruz 
p65         Cell Signaling 
phospho-p65        Cell Signaling 
TBK1        Cell Signaling 
Phospho-TBK1       BD 
APS        Sigma 
ASCC1 cDNA clone in CMV expression vector  OriGene 
Blasticidin S        InVivo 
Boric Acid        Sigma 
Bovine serum albumin      Sigma 
Bradford reagent dye       Bio-Rad 
Bromophenol blue       Sigma 
Chloroform        Sigma 
Chloroquine        Sigma 
CIP         New England Biolabs 
Coelenterazine      Insight Biotech 
DEPC-treated water       Ambion 
DMEM        Invitrogen 
DMSO        Sigma 
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DNA ladder (1Kb) & Loading dye (6X)    Promega 
dNTPs        Promega 
DTT         Sigma 
E.coli - TOP 10 competent cells    Invitrogen 
EDTA        Sigma 
Ethanol        Sigma 
Ethidium bromide      Sigma 
FBS         Invitrogen 
Glacial acetic acid       Merck 
Glycerol       Sigma 
Glycine        Sigma 
Goat Serum        Vector Laboratories 
GoTaq Flexi DNA Polymerase     Promega 
High speed plasmid midi kit      Qiagen 
HEPES       Sigma 
Hoescht stain       Sigma 
Human HEK 293 cell line      InVivo 
Hydrochloric acid       Merck 
Hygrogold       InVivo 
Igepal         Sigma 
IL-1β (human)      Cell signaling 
IRDye 800CW Goat Anti-Rabbit     Licor Biosciences 
IRDye 680 Donkey Anti-Mouse    Licor Biosciences 
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Isopropanol        Sigma 
Kanamycin        Sigma 
L-glutamine        Invitrogen 
Lipofectamine 2000       Invitrogen 
Lipopolysaccharide       Alexis 
Luciferase substrate       Promega 
Magnesium Chloride       Sigma 
β-Mercaptoethanol       Sigma 
Methanol        BDH 
Microlon 96-well plates      Greiner 
MMLV Reverse Transcriptase     Promega 
Morpholinos        Gene Tools 
Nitrocellulose       Schleicher & Schuell 
NF-κB IRDye Labelled Oligonucleotides    Licor Biosciences 
OptiMEM        Invitrogen 
Paraformaldehyde       Sigma 
Para-p-phenylendiamine      Sigma 
PBS         Oxoid 
pcDNA 3.1/Zeo       Invitrogen 
Penicillin / Streptomycin / Glutamine   Invitrogen 
PMSF         Sigma 
Poly(I:C)        InVivo 
Polybrene        Sigma 
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Poly-L-Lysine       Sigma 
Ponceau        Sigma 
Prestained molecular weight marker     Fermentas 
Protease inhibitor mixture      Roche 
Protease inhibitor mixture (EDTA free)    Roche 
Protein A/G-agarose       Santa Cruz 
Proteinase K        Sigma 
Protogel       National Diagnostics 
Puromycin        Sigma 
QIAquick gel extraction kit      Qiagen 
QUANTI-Blue      Invitrogen 
Random primers       Invitrogen 
Reverse Transcription System     Promega 
RNase Zap        Ambion 
RPMI        Invitrogen 
SB203580        Cell Signaling 
SDS         Sigma 
shRNA        Sigma 
siRNA        Invitrogen 
Scrambled siRNA       Invitrogen 
Skim milk powder       Marvel 
Sodium chloride (NaCl)      Sigma 
Sodium Deoxycholate (C24H39O4Na)    Sigma 
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Sodium hydroxide (NaOH)      Sigma 
Sodium orthovanadate (Na3VO4)     Sigma 
Sulphuric acid       Sigma 
SensiMix SYBR Low-ROX-kit     Bioline 
Synthetic oligonucleotides     MWG Biotech 
TEMED        Sigma 
Tissue culture ware      Greiner 
TK Renilla        Promega 
Tri reagent        Sigma 
Tris-base        Sigma 
Tris-HCl        Sigma 
Triton-X        Sigma 
Trypsin/EDTA      Invitrogen 
Tryptone        DIFCO 
Tween-20        Sigma 
Whatmann paper       AGB 
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2.1.2  Gifts 
 
Cell lines:  
 
HEK293 cells and HEK293 stably expressing TLR3 or TLR4 - Prof. Douglas T. 
Golenbock (The University of Massachusetts Medical School, Worcester, Massachusetts 
01605, USA).  
U373 cell line – Dr. Sinead Miggin (Biology Department, NUI Maynooth, Ireland).  
 
Constructs:  
 
Flag-tagged MyD88 – Dr M. Muzio (Mario Negri Institute, Milan, Italy)  
NF-κB-luciferase reporter construct – Prof. Luke O’Neill (Trinity College Dublin,    
Ireland)  
GFP-tagged IκBL – Dr. Ross McManus (Trinity College Dublin, Ireland)  

Myc-tagged IL-17RD, Flag-tagged TRAF6 – Dr. Mark Mellett (National University of 
Ireland, Maynooth)
 
FLAG-tagged Act1 from Dr. Antonio Leonardi (Federico II University of Naples, Italy) 
2.1.3 Commercial Plasmids 
Myc-tagged IL-17RD TIR purchased from Genscript (New Jersey, USA)  
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2.2 Methods 
2.2.1 Cell culture 
2.2.1.1  Adherent cell lines. 
 
Human embryonic kidney (HEK) 293 cells stably transfected with the SV40 large T 
antigen, TLR3 or TLR4  receptors, human U373 astrocytoma cells and murine bone marrow 
derived macrophage (BMDM) cells were maintained in Dulbecco‘s Modified Eagle Medium 
(DMEM), which was supplemented with 10% (v/v) foetal bovine serum (FBS), 100 U/ml 
penicillin and 100 µg/ml streptomycin.  Cells were maintained in a 37ºC humidified 
atmosphere with 5% CO2.  Cells were passaged every 2 to 3 days using 1% (w/v) 
Trypsin/ethylenediaminetetraacetic acid (EDTA) solution in phosphate-buffered saline 
(PBS).  G418 (500 µg/ml) was used to select for the stably transfected TLR cell lines. 
 
2.2.1.2   Isolation of primary murine BMDMs. 
 
To isolate BMDMs, tibias and femurs from either IL-17RD
+/+
 and IL-17RD
-/- 
mice 
were removed using sterile technique and the bone marrow was flushed with fresh medium. 
To obtain macrophages, cells were plated in medium supplemented with 20 ng/ml M-CSF 
and maintained at 37 °C in a humidified atmosphere of 5% CO2 for 4-6 days. 
 
2.2.2   Transient transfection of cells 
2.2.2.1  Transfection of cells for luciferase reporter assay  
 
HEK293 T/TLR3/TLR4 cells were seeded at 2x10
5
 cells/ml (200 μl DMEM/well) in 
96-well plates and allowed to adhere for 24 h to approximately 70% confluency.  Cells were 
transfected using Lipofectamine 2000.  For each well to be transfected, 25 µl of OptiMEM 
was mixed with the DNA.  DNA mixes were made up for the appropriate luciferase 
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construct. Lipofectamine 2000 (0.4 μl) was diluted in OptiMEM (25 µl) per sample and the 
reaction was mixed gently and left at room temperature for 5 min.  After the incubation, the 
Lipofectamine/OptiMEM solution was added to the DNA/OptiMEM mix (total volume 50 µl 
per well to be transfected) and the combined reaction was mixed gently and incubated at 
room temperature for 20 min.  The transfection mixture was then added to each well and 
mixed gently by tapping the side of the plate.  Each sample was transfected in triplicate.  24 h 
after transfection, cells were pre-treated with various agents for indicated timepoints.  The 
supernatants were subsequently removed and stored at -20°C and then assayed for cytokine 
production using sandwich enzyme-linked immunosorbent assay (ELISA), while cell lysates 
were generated and used to measure luciferase activity 
 
2.2.3   Luciferase assays 
 
HEK293 TLR3/TLR4 were all seeded at 2 x 10
5
cells/ml in 96-well plates (200 µl 
DMEM/well) and grown for 24 h.  All transfections were performed using Lipofectamine 
2000 transfection reagents (as described in sections 2.2.2.1).  Details of the constructs 
transfected are given below.    24 h post transfection, cells were treated with various agents.  
The medium was then removed from the cells and reporter lysis buffer (100 µl, Promega) 
was added to each well using a multi-channel pipette.  The plate was then wrapped in 
aluminium foil and placed on a rocker for 30 min at room temperature before being placed at 
-80
o
C for a minimum of 1 h.  After thawing at room temperature, aliquots (40 µl) of each 
were assayed for firefly luciferase activity using firefly luciferase substrate (40 µl, Promega), 
while Renilla luciferase activity was assayed using coelenterazine (0.1 µg/ml in PBS).  
Luminescence was monitored with a Glomax microplate luminometer (Promega). 
 
2.2.3.1  NF-κB assay 
 
To measure activation of the NF-κB pathway, cells were transfected with NF-κB -
regulated firefly luciferase reporter plasmid (80 ng) and constitutively expressed  Renilla-
luciferase reporter construct phRL-TK (40 ng).  The total amount of DNA was maintained at 
240 ng using pcDNA3.1. 
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2.2.4   Propagation of DNA 
 
2.2.4.1   Rapid transformation of competent E.coli cells 
 
Commercially available TOP 10 competent E.coli bacterial cells were used for 
propagation of plasmids of interest.  Plasmids (100 g/ml) were added to five times as much 
TOP10 cells, i.e. 1 μl (100 ng plasmid) was added to 5 μl cells.  DNA was mixed gently with 
cells by pipetting gently up and down and allowed to incubate on ice for 30 min.  The 
plasmids were allowed to enter the bacterial cells by heat shocking the mixture at 42
o
C for 45 
seconds.  The cell membrane became permeable allowing plasmid entry and cooling on ice 
for 2 min makes the cell membrane once again impermeable.  The transformed cells were 
then incubated in 1 ml Luria Bertoni (LB) broth (1% (w/v) tryptone, 0.5% (w/v) yeast extract, 
85 mM NaCl) at 37
o
C on a shaker for 1 h.  Bacterial cells were centrifuged at 9000 g for 3 
min and 850 μl supernatant was removed.  The pellet was resuspended in the remaining LB 
broth and plated out onto LB agar plates (LB broth with 1.5% (w/v) agar) containing 
ampicillin (50 μg/ml).  Plates were inverted and incubated overnight at 37oC.  Plates were 
then stored at 4
o
C. 
 
2.2.4.2   Small scale preparation of DNA from E. coli cells 
 
LB broth (2 ml) containing the relevant antibiotic (50 μg/ml) was inoculated with a 
single transformed E. coli colony from an agar plate.  The culture was incubated on a shaker 
overnight at 37
o
C.  Small plasmid preparations were made using the Qiaprep Spin Miniprep 
kit from Qiagen Inc.  The bacterial cells were centrifuged at 9000 g for 3 min and the 
supernatant was discarded and the plasmid DNA was extracted as outlined in the 
manufacturer‘s handbook.  DNA was quantified using a Cary spectrophotometer. After 
diluting the DNA appropriately in Tris-EDTA (TE) buffer, pH 8.0, (10 mM Tris-HCl, 1 mM 
EDTA) the absorbance of the solution was measured at 260 nm and 280 nm.  All samples 
used had an optical density (OD) 260/OD280 ratio in the range of 1.7 to 1.9. Ratios below 1.7 
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or above 1.9 indicated RNA or protein contamination, respectively. The concentration was 
calculated using the formula: 
µg/ml DNA = 50 µg/ml/OD260 x (OD260 measured) x (dilution factor). 
 
2.2.4.3   Large scale preparation of DNA from E. coli cells 
 
A starter culture of LB broth (2 ml) containing the relevant antibiotic (50 μg/ml) was 
inoculated with a single transformed E.coli colony and incubated on a shaker at 37
o
C for 6-8 
h. This was then added to a larger volume of LB broth (100 ml) containing the relevant 
antibiotic and incubated at 37
o
C overnight shaking.  Large plasmid preparations were made 
using the Qiagen high speed plasmid midi kit from Qiagen.  The bacterial cells were 
centrifuged at 3000 g for 40 min and the supernatant was discarded and the plasmid DNA 
was extracted as outlined in the manufacturer‘s handbook.  DNA was quantified as outlined 
in Section 2.2.4.2. 
 
2.2.5   Generation of supernatants for ELISA 
U373 astrocytoma cells were seeded in 96-well plates at a density of 2x10
5
 cells/ml. 
BMDM cells were seeded in 96-well plates at a density of 5x10
5
 cells/ml.  Cells were grown 
for 24 h. Next day, cells were stimulated with ligands for 24 h and supernatants were 
collected from each well and stored at -20
o
C until analysis of cytokine production by ELISA 
was carried out according to manufacturer’s instruction. 
 
2.2.6   siRNA studies 
 
2.2.6.1  Transfection of siRNA  
 
Pre-designed siRNA targeting IL-17RD was purchased from Invitrogen (sense 
sequence: 5'  – UCUUGAAGUGCUCUGCCUCCUUCUC  -3') and a corresponding 
scrambled siRNA was designed (sense sequence 5'  –
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GAGAAGGAGGCAGAGCACUUCAAGA - 3') and purchased from Invitrogen. HEK293 
TLR3 cells were seeded at 1.5 x 10
5
cells/ml in 6-well plates (3 ml DMEM/well). Cells were 
grown for 24 h to approximately 60 % confluency.  The appropriate amount of Sef siRNA or 
scrambled siRNA (for a final concentration of 25 nM/well) was diluted in OptiMEM (250 
μl). Lipofectamine 2000 (4 μl) was diluted in OptiMEM (250 μl) per sample, and the reaction 
was mixed gently and left at room temperature for 5 min. After the incubation, the 
Lipofectamine/OptiMEM solution was added to the siRNA mix (total volume 500 μl per well 
to be transfected) and the combined reaction was mixed gently and incubated at room 
temperature for 20 min. 500 μl sample was added to each well and mixed gently by rocking 
the plate back and forth. Cells were incubated for 48 h prior to generation of extracts for 
Western immunoblotting or extraction of RNA for quantitative real-time PCR. 
 
2.2.7 Co-immunoprecipitations (CoIPs) 
 
HEK293 TLR4 cells were transfected with Lipofectamine 2000 as previously 
described in section 2.2.2.1 with equal amounts (2 μg) of expression constructs encoding the 
potential interaction partners. Cell extracts were generated on ice or at 4
o
C as follows. Cells 
were first washed with pre-chilled 1X PBS (1 ml) then lysed with pre-chilled CoIP lysis 
buffer (50 mM Tris-HCl, pH 7.5, containing 150  mM NaCl, 0.5 % (v/v) igepal and 50 mM 
NaF, with 1 mM Na3VO4, 1 mM dithiothreitol (DTT), 1 mM phenylmethylsulfonyl fluoride 
(PMSF) and protease inhibitor mixture (leupeptin (25  μg/ml), aprotinin (25  μg/ml), 
benzamidine (1 mM), trypsin inhibitor (10 μg/ml)) for 30 min on a rocker at 4oC. Lysates 
were scraped into pre-chilled 1.5 ml microcentrifuge tubes and centrifuged at 12,000 g for 10 
min at 4
o
C. Supernatants were removed to fresh tubes (a sample retained for whole cell lysate 
analysis) and incubated for 30 min with mouse or rabbit immunoglobulin (Ig) G (1 μg) 
(depending on the primary antibody) and Protein A/G agarose beads (10 μl) on a rotor at 4oC. 
Samples were centrifuged at 1000 g for 5 min at 4
o
C to pellet beads with nonspecifically 
bound protein and supernatants were removed to fresh pre-chilled tubes. Samples were 
incubated overnight with primary antibody (1 μg). The following day Protein A/G agarose 
beads (20 μl) were added to each sample and they were again incubated at 4oC overnight. The 
subsequent day samples were centrifuged at 16,000 g for 1 min. The supernatant was 
removed and the beads were washed with CoIP lysis buffer (500 μl) and subject to re-
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centrifugation. This step was repeated four times. 40 μl of 1X sample buffer (0.125 M Tris-
HCl, pH 6.8, containing 20 % (w/v) glycerol, 4% (w/v) SDS, 1.4 M β-mercaptoethanol and 
0.0025 % (w/v) bromophenol blue) was added to the beads for 30 min at RT. Samples were 
centrifuged at 16,000 g for 2 min and the supernatant was subsequently boiled at 100
o
C for 
10 min and analyzed using SDS polyacrylamide gel electrophoresis and western blotting 
(section 2.2.8). 
 
2.2.8   Western blot analysis 
 
2.2.8.1  SDS-polyacrylamide gel electrophoresis (SDS-PAGE)  
 
SDS-PAGE was conducted according to the method of Laemmli  (Laemmli 1970), as 
modified by Studier  (Studier 1973). Samples and appropriate prestained (26.6-180 kDa) 
protein markers were loaded into separate wells. Electrophoresis was performed at 80 V 
through a 5 % SDS polyacrylamide stacking gel and then through a 10 % SDS 
polyacrylamide resolving gel at 110 V for 1-1.5 h, depending on the size of the proteins being 
electrophoresed. 
 
2.2.8.2 Immunoblotting 
 
Following separation by electrophoresis, the proteins were transferred 
electrophoretically to nitrocellulose membranes in a wet transfer unit at 150 V for 1.5 h using 
Whatmann and nitrocellulose pre-soaked in cold transfer buffer (25 mM Tris Base, 0.2 M 
glycine and 20 % (v/v) methanol) for 10 min. Following transfer, non- specific binding was 
blocked by incubating the nitrocellulose membranes at room temperature for 1 h (or 
overnight) in TBS (20 mM Tris-HCl pH 7.5, containing 0.05% (v/v) Tween 20 and 0.5 M 
NaCl) containing 5 % (w/v) skimmed milk powder. The membranes were then washed 3 
times for 5 min each in TBS prior to incubation at 4
o
C overnight with the primary antibodies 
diluted in TBS containing 5 % (w/v) skimmed milk powder or BSA. The membranes were 
subsequently subjected to 5 x 10 min washes in TBS prior to incubation with secondary 
antibody (1:5000 dilution) specific for the primary antibody in question (anti-rabbit or anti-
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mouse) in TBS containing 5 % (w/v) skimmed milk powder for 1.5 h in the dark at room 
temperature. The membranes were then washed a further 5 times for 10 min each in TBS in 
the dark. The immunoreactive bands were detected using Odyssey Infrared Imaging System 
from Licor Bioscience, according to the instructions of the manufacturer. 
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1
o 
antibody    Dilution    2
o
 antibody* 
β-actin    1:5000    mouse 
Myc                1:1000    mouse 
Erk1/2    1:1000    rabbit 
Phospho Erk1/2   1:1000    rabbit 
Flag               1:1000    mouse 
HA     1:1000    mouse 
IκBα                                        1:500                                       rabbit 
JNK    1:1000    rabbit 
Phospho-JNK    1:1000    rabbit 
IRF-3                   1:1000               rabbit 
p38     1:1000    rabbit 
Phospho-p38    1:1000    rabbit 
Phospho-IRF-3                       1:1000                                     rabbit 
p65     1:1000    rabbit  
Phospho-p65    1:1000    rabbit 
Phospho-Serine   1:200     rabbit 
RIG-1    1:1000    rabbit 
COX-2   1:200    rabbit 
TBK1     1:1000     rabbit 
Phospho-TBK1   1:1000    rabbit 
* All secondary antibodies were used at a dilution of 1:5000. 
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2.2.9  Lentiviral shRNA-IL-17RD infection  
 
2.2.9.1  Lentiviral production 
 
HEK293 T cells were seeded at 2 x 10
5
 cells/ml in 6-well plates (3 ml DMEM/well) 
and grown for 24 h to approximately 80 % confluency. The cells were transfected as in 
section 2.2.2.2. The DNA mixture contained packaging plasmid (900 ng), envelope plasmid 
(100 ng) and the sh-pLKO.1 vector (1 μg). IL-17RD shRNA sequences were as follows: 
 
Sef shRNA 1  5’- CAGGGATACAAGTTCAACATC -3’ 
Sef shRNA 2  5’- AGGTCAGATTCAGAGGAAGAG -3’ 
 
A control shRNA (CT) was also used in the transfection. The control shRNA is a non-
targeting shRNA vector that will activate the RNA-induced silencing complex (RISC) and 
the RNAi pathway, but it does not target any human or mouse genes. The short-hairpin 
sequence contains 5 base pair mismatches to any known human or mouse gene. The shRNA 
IL-17RD and shRNA control plasmids were purchased from Sigma. To remove the 
transfection reagent, the media was changed 24 h post-transfection and replaced with fresh 
high serum (30 %) growth media. The cells were then incubated for 24 h. The media 
containing lentivirus were harvested ~ 40 h post-transfection and transferred to a 
polypropylene tube for storage at -20°C. The media was replaced with fresh high serum (30 
%) growth media and the cells were incubated for 24 h. The virus was harvested one more 
time and after the final harvest the packaging cells were discarded. 
 
2.2.9.2 Lentiviral infection 
                                                                         
 U373 cells were seeded at 2 x 10
5
 cells/ml in 6-well plates (3 ml/well RPMI or 
DMEM, respectively). U373 cells were incubated overnight prior to infection to allow the 
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cells to adhere. The growth media was then removed and replaced with fresh media 
containing polybrene (8 μg/ml) and 600 μl of virus. The plates were incubated at 37oC.  The 
media was removed 24 h post-infection and replaced with fresh growth media containing 
puromycin (10 μg/ml) to select for cells transduced with shRNA. The polyclonal population 
of cells were cultured for 2-3 weeks and used for ELISA and Western Blot experiments. 
 
2.2.10 Isolation of RNA and cDNA synthesis 
 
2.2.10.1 Isolation of total RNA from HEK293, U373 & BMDM cells  
 
In order to minimise RNA degradation, a number of precautions were taken 
throughout the following procedures. All water and salt based solutions were treated with 
diethylpyrocarbonate (DEPC) (0.2 % v/v). Certified RNasefree plasticware was used. Before 
commencing, equipment was wiped with “RNase Zap”, an RNase decontamination solution. 
Gloves were worn at all times and regularly changed.  Total RNA was isolated using the Tri 
Reagent (Sigma) as per manufacturer’s instructions. The amount of isolated RNA was 
quantified by measuring the absorbance at wavelengths of 260 nm and 280 nm on a 
spectrophotometer, where an absorbance of 1 unit at 260 nm is ~ 40 μg/ml.  Pure RNA 
preparations have an OD260/OD280 ratio of 1.6-1.8.  Extracted RNA was stored at -80
o
C. 
 
2.2.10.2 Synthesis of first strand cDNA from mRNA 
 
1 μg of RNA was placed in nuclease-free microcentrifuge tubes and incubated for 10 
min at 70
o
C. The mixture was then chilled on ice and centrifuged briefly. The following 
components were then added: 
MMLV RT      0.25 μl 
dNTPs (10 mM)    2 μl 
5X MMLV Buffer    4 μl 
RNasin (40 U/μl)    0.5 μl 
Random Primers (0.5 μg/μl)             1 μl 
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Nuclease-Free Water    to 20 μl 
The reaction mixture was incubated for 10 min at RT allowing the primers to anneal to the 
RNA. Next, the reaction was incubated at 42°C for 1 h. MMLV RT was then deactivated by 
heating to 95
o
C for 5 min followed by cooling to 0-5
o
C for 5 min. Generated cDNA was 
stored at 4
o
C for short-term storage or  -20
o
C for long-term storage.  
 
2.2.10.3 PCR amplification of DNA 
 
PCR products were amplified using either complementary DNA (cDNA) or plasmid 
DNA as template. Synthesised primers were designed based on deposited GenBank 
sequences. The GC-RICH PCR System, which contains a mixture of Thermophilus aquaticus 
(Taq) polymerase and a high fidelity proofreading polymerase, was used for the amplification 
of PCR products. The standard PCR conditions below were used to amplify the target 
sequence.  
  Template (100ng cDNA)   1 μL  
  5X Enzyme Buffer    10 μL  
  GC-Rich Resolution Buffer   5 μL 
  Primers (10 pmol/ μL)   2.5 μL each 
  dNTP mix (10mM each)   4 μL 
  Enzyme Mix     1 μL 
  PCR-grade water    50 μL 
 
Each reaction was heated to 94
o
C for 2 min. Then this step was followed by a cycle of 94
o
C 
for 30 s, a target-specific annealing temperature (TA) for 30 s, and 72
o
C for a polymerase 
specific elongation time based on the size of the sequence to be amplified. The appropriate 
cycle number was experimentally determined for each target to ensure that the reaction was 
still in the linear phase upon termination. Samples were then incubated at 72
o
C for 10 min 
and stored at 4
o
C if necessary. 
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2.2.10.4  Quantitative Real Time PCR  
 
Cells were seeded (1.5 x 10
5
 cells/ml; 3 ml) into 6-well plates and grown for 24 h to 
approximately 60 % confluency. Cells were washed with 1X PBS (1 ml) and RNA was 
extracted, as described in section 2.2.10.1. cDNA was then generated as described in section 
2.2.10.2. Samples were assayed by quantitative real time PCR for levels of IL-17RD, IFN-β, 
KC, IL-6, IL-8 and RANTES cDNA using SensiMix SYBR Low-ROX kit (Bioline). PCR 
was conducted with the CFB-322001G Opticon thermal cycler (Bio-Rad Laboratories). 
Reactions were performed using pre-validated primers (Eurofins MWG Operon). 
Accumulation of gene-specific PCR products was measured continuously by means of 
fluorescence detection over 40 cycles. Samples were initially heated for 10 min at 95
o
C. This 
was followed by 10 seconds at 95
o
C, 10 seconds at 59
o
C and 1 min at 72
o
C for 40 cycles. 
Gene expression was calculated relative to the endogenous control and analysis was 
performed using the 2
-ΔΔCT 
method. 
 
2.2.11  Determining protein concentration – Method of 
Bradford  
 
Protein content of BSA standards and cell extracts was measured by the method of 
Bradford (Bradford 1976). Standards and extracts (10 μl) were diluted in water and mixed 
with aliquots (190 μl) of Bradford protein reagent (Bio-Rad), diluted 1:5 in distilled water, by 
pipetting up and down. A blank was prepared using the same dilution of water. Absorbance 
was measured for each sample in a 96-well plate at 590 nm using ELx800
TM
 microplate 
reader with Gen5 Data Analysis Software. Six protein standards of BSA (10, 8, 6, 4, 2 and 0 
μg/μl) were made and used to construct a standard curve which was subsequently used to 
determine protein concentration of the cell extracts. 
 
2.2.12  Type I Interferon Blue Assay 
B16-Blue™ IFN-α/β Cells (Invivogen) were seeded (1.5 x 105 cells/ml; 200 μl) in 96 
well plates. 20 μl of supernatant was added to each well and incubated at 37°C in a 5% CO2 
incubator for 20 h. QUANTI-Blue™ was prepared following the manufacturer’s instructions. 
41 
 
180 μL of resuspended QUANTI-Blue™ was added to a flat-bottom 96-well plate. 20 μl of 
induced B16-Blue™ IFN-a/b Cells supernatant was added to each well. The plate was 
incubated at 37°C for 1-5 h. Absorbance was measured for each sample in a 96-well plate at 620 
nm using ELx800TM microplate reader with Gen5 Data Analysis Software. 
 
2.2.13  Mice  
 
2.2.13.1  Generation of Mice 
 
IL-17RD-deficient mice were generated by the German Genetrap Consortium using 
its proprietary technology (Clone ID: D065E01) (Fig. 3.7a). The genetrap targeting vector, 
which contains a promoter-less reporter gene downstream of a splice acceptor and a 
selectable marker gene (β-Geo for β-Galactosidase neomycin-resistant fusion gene) was 
incorporated into the il-17rd gene after the first exon. The targeting vector contains loxP, f3 
and lox5171 sites allowing conditional mutagenesis or recombinase-mediated cassette 
exchange. After the targeting vector was transfected into embryonic stem cells, G418-
resistent colonies were selected and screened by PCR. Homologous recombinants were 
microinjected into female C57BL/6 background mice and heterozygous F1 progeny were 
intercrossed to obtain IL-17RD
-/-
 mice. IL-17RD
+/-
 mice were bred to generate age- and sex-
matched IL-17RD
+/+
, IL-17RD
+/-
, IL-17RD
-/-
 mice for experiments.  
 
2.2.13.2  Breeding and maintenance 
 
Breeding, colony expansion and maintenance were performed in the Bioresource 
facility of National University of Ireland (NUI) Maynooth.  All animals were housed in a 
barrier unit, in IVC cages with HEPA filters. Animals were monitored regularly for 
microorganisms according to FELASA recommendations. All animal experiments were 
performed in accordance with the regulations and guidelines of the Irish Department of 
Health and protocols approved by the Research Ethics committee of NUI Maynooth. 
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2.2.13.3 Genotyping of mice 
 
Mice were genotyped by PCR analysis of DNA isolated from ear punches using 
primers 1 5ꞌ-TGTGGTAGCCAAAGACTGCTTCATG-3ꞌ, 2 5ꞌ-
ATAGGTCACTTGCAAATCC-3ꞌ, 3 5ꞌ-GGACAGGATAAGTATGA CATCATC-3ꞌ, 4 5ꞌ-
CTGGCGTAATAGCGAAGAGG-3ꞌ and 5 5ꞌ-CCGCCACATA TCCTGATCTT-3ꞌ.  PCR 
analysis using primers 1 and 2 generates a fragment of 449 bp for the WT allele. Primers 1 
and 3 generate a fragment of 1103 bp for the knockout allele (Fig. 3.7b). To further confirm 
the presence of the genetrap cassette primers 4 and 5 amplify a region of the β-Geo insert at a 
size of 508 bp and this is only found in IL-17RD
+/-
 and IL-17RD
-/-
 mice. 
 
2.2.13.4 Peritoneal and Pulmonary administration of IL-17A 
 
Age- and sex-matched IL-17RD
+/+ 
and IL-17RD
-/-
 mice were treated with 0.5 g of 
IL-17A (R & D Systems) by intraperitoneal injection, or 1 g of the formyl-Met-Leu-Phe 
peptide (Sigma) prepared in endotoxin-free PBS and control mice were injected with 
endotoxin-free PBS. For the exogenous MIP-2 administration experiment mice were 
subjected to intraperitoneal injection of 0.5 g of IL-17A or PBS 1 h prior to treatment with 
recombinant murine MIP-2 (30 ng) for 2 h. The peritoneal cavity was lavaged with 2 ml ice-
cold PBS at 0-6 h post-treatment. Peritoneal cells were counted and quantified by flow 
cytometry and differential cell counting. To induce pulmonary neutrophilia, 0.5 g IL-17A 
was introduced intra-nasally to groups of age-matched female IL-17RD
+/+ 
and IL-17RD
-/-
 
mice. After 4 h, bronchoalvelolar lavage (BAL) was performed and cellular infiltration into 
the lung was quantified by differential cell counts on BALs. Lung tissue was perfused and 
fixed in 10% formalin saline. Paraffin-embedded sections were stained with hematoxylin and 
eosin to assess leukocyte infiltration and pulmonary inflammation. 
 
2.2.14  Flow cytometry 
 
Infiltrating cells were analyzed by surface marker expression by flow cytometry with 
data collection on a CyAn (Beckman Coulter), as described (Ludwig et al. 2010). Data were 
analyzed using  FlowJo software (Tree Star). Cells were stained using PerCP anti-CD11b 
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(M1/70), PE anti-Ly6G (RB6-8CS) and APC anti-F4/80 (BM8). Flow buffers used contained 
2 mM EDTA to exclude doublets. Using appropriate isotype-controls, gates were drawn and 
data were plotted on logarithmic scale density- or dot-plots. 
 
2.2.15 Slide preparation and differential cell counting 
 
Slides were prepared from BAL fluid or peritoneal lavage (50,000 cells/slide) using a 
cytospin (Thermo-Shandon). All slides were stained with Wright-Giemsa (Thermo-Shandon) 
to depict leukocyte subsets. A total of 200 leukocytes were counted per slide. 
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3.1 Introduction 
 The TLR family of PRRs and their associated adaptor proteins have emerged as vital 
components of the innate immune system which ignite the inflammatory response in reaction 
to infection from microbial agents. However, the pathways initiated by this family of 
receptors require numerous levels of regulation to keep in check aberrant inflammatory 
signals, the initial steps towards chronic inflammation. Focus on TLR signalling has moved 
from delineating the stepwise pathways to the TIR domain containing proteins which are of 
interest due to TLRs utilising the different adaptors to tailor specific response to a variety of 
infections.  
 IL-17RD has, up until now, been characterised as an antagonist of FGF signalling 
(Tsang and Dawid 2004). The studies have demonstrated that IL-17RD localises with and is 
under the control of fgf genes, hence the alternative name “Sef” (similar expression to fgf 
genes). Different targets have been revealed for IL-17RD in FGF signalling. IL-17RD 
inhibits at the receptor level but also downstream at the level of MEK (Furthauer et al., 2002; 
Kovalenko et al., 2003; Tsang et al., 2002; Xiong et al., 2003). IL-17RD also interferes with 
the dissociation of ERK from MEK, impeding the translocation of ERK to the nucleus (Torii 
et al., 2004). The regulation of these pathways by IL-17RD is expected to be of physiological 
importance and this has already been reported in the case of FGF signalling where IL-17RD 
is downregulated in a variety of carcinomas (Zisman-Rozen et al. 2007). In fact, IL-17RD 
may function chiefly as a tumour suppressor given that a result of its loss is an increase in 
tumorigenesis. IL-17RD could function in determining cell fate by the inhibition of FGF and 
NF-κB pathways, which promote cell growth and cell survival and apoptosis (Yang et al. 
2004). Another reason as to why IL-17RD may play a role in innate immunity could be due 
to its expression profile which highlights that IL-17RD is found in large amounts in the brain, 
the ovaries and testes which are immune-privileged sites in the body (Novatchkova et al. 
2003). An increased amount of IL-17RD in these organs may confer protection against 
undesired inflammatory responses. 
Importantly, IL-17RD was reported to have a TIR-like domain (Novatchkova et al. 2003). 
This TIR-like domain is characterised as a SEFIR (Sef and IL-17Rs) domain as it lacks box 3 
of the TIR domain and shares significant homology with other Sef proteins and IL-17Rs 
(Novatchkova et al. 2003). Box 1 and 2 of the TIR domain have been shown to relate to TIR-
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TIR interactions while Box 3 is associated with receptor localisation (Slack et al. 2000) Over 
the last 10 years or so, there has been more and more investigation into the proteins that 
regulate TLR signalling and increasingly it has been shown that this regulation is carried out 
by a significant number of TIR domain containing proteins. For example, SIGGIR, which 
contains a putative extracellular immunoglobulin domain in addition to the TIR domain 
(O’Neill 2003). Given that IL-17RD contains a TIR-like domain we initially looked at its 
effect on pathways regulated by TLRs with a special emphasis on the NF-κB and IRF 
pathways and transcription of TLR responsive genes. 
IL-17RD, which was first described in Zebrafish, exhibits considerable conservation across 
species (Moseley et al. 2003). A 739 amino acid transmembrane protein, IL-17RD is 
composed of an N terminal signal peptide, an extracellular fibronectin-III (Fn-III) like 
domain and the previously mentioned intracellular SEFIR domain. In addition to this Fn-III 
domain, the extracellular region is also characterised by a putative Ig (Immunoglobulin) 
domain (Tsang et al. 2002; Xiong et al. 2003). Tandem Fn domains in the extracellular 
domain are also shared by the IL-17 receptors and are a common feature of cytokine 
receptors.  The IL-17 family of cytokine receptors share the greatest homology with IL-17RD 
Novatchkova et al. 2003). They also share similar transmembrane domains, SEFIR domains 
and polar residue-rich C-termini (Novatchkova et al. 2003). Whilst recent studies have 
outlined key immunoregulatory roles for the various IL-17R members, IL-17RD remains an 
orphan receptor without a physiological role in IL-17 signalling, apart from a report in which 
overexpression of IL-17RD was shown to co-operate with IL-17RA (Rong et al. 2009). This 
thesis describes, for the first time, an important biological function of IL-17RD in IL-17 
signalling. We also propose a possible role of IL-17RD in non-TLR/IL-17 pathways. Overall, 
the studies described here highlight important regulatory roles for IL-17RD in innate immune 
signalling pathways. 
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3.2 Results  
3.2.1  Suppression of endogenous IL-17RD expression enhances the activation of TLR 
signalling components 
 In order to characterise the physiological role of IL-17RD in TLR signalling, the 
effects of IL-17RD knockdown on TLR ligand induced phosphorylation of important 
downstream signalling components were assessed. U373 astrocytoma cell lines were 
transduced with lentivirus to stably express IL-17RD specific shRNA or control shRNA. 
Knockdown efficiency was regularly checked in these U373 shRNA stable cell lines and 50-
75% knockdown of il-17rd mRNA was consistently achieved compared with the control 
shRNA (Fig. 3.1). Cells were treated with LPS (Fig. 3.2) or Poly I:C (Fig. 3.3) over various 
timepoints. IL-17RD shRNA was shown to potentiate the phosphorylation of TLR signalling 
components in cells treated with LPS and Poly I:C. Knockdown of IL-17RD in these cells 
resulted in augmented LPS induced phosphorylation of IκB and IKK relative to control 
shRNA cells (Fig 3.2). In the case of Poly I:C, there is increased phosphorylation of TBK1 at 
earlier timepoints and more  prolonged and sustained phosphorylation of  IRF3 in IL-17RD 
knockdown cells relative to control cells (Fig 3.3). Such differences between control and 
shRNA cells strongly suggest IL-17RD may act as a negative regulator of TLR signalling.    
3.2.2  IL-17RD knockdown augments TLR mediated cytokine mRNA induction 
 Given that the above results highlight a potential role for IL-17RD in TLR signalling, 
it was necessary to probe the regulatory effects on NF-κB and IRF responsive genes in 
control and IL-17RD shRNA cells. IL-6 was chosen as a representative NF-κB gene. IL-6 is 
produced by cells such as macrophages and endothelial cells and is released in response to 
infection, burns and neoplasia. It has a wide range of functions such as acute phase protein 
induction and B and T cell growth and differentiation (Ray et al 1989; Janeway et al 2001; 
Fernandez – Botran, 1995). As NF-κB activates IL-6 production, we investigated if the 
absence of IL-17RD would have an effect on its induction. Cells were treated with LPS at 3 
hour and 6 hour intervals (Fig 3.4). IL-6 mRNA was quantitated by real time PCR. IL-17RD 
shRNA led to a modest enhancement of LPS induced expression of IL-6 mRNA relative to 
control shRNA cells. However, at 6 hours there was a pronounced (~ 50%) augmentation of 
Poly(I:C) induced expression of IL-6 mRNA in the IL-17RD shRNA cells. The type 1 
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interferon, IFN β, was chosen as an IRF responsive gene. Interferons are potent antiviral 
agents, not normally expressed in cells. Viral infection of a cell causes interferons to be 
produced and released. It subsequently binds to target cells and induces an antiviral state. The 
expression of IL-17RD shRNA greatly augmented the ability of Poly (I:C) to induced IFN β 
expression at 6 hours post Poly (I:C) stimulation (Fig 3.5). Consequently, IL-17RD appears 
to negatively regulate activation of NF-κB and IRFs and production of important 
proinflammatory genes such as IL-6 and IFN β in response to TLRs. . 
3.2.3  Knockdown of IL-17RD increased TLR-induced cytokine production 
 Since the above studies indicated that IL-17RD negatively regulates the expression of 
TLR-responsive genes at the mRNA, we were keen to explore the effects of loss of IL-17RD 
on expression of these genes at the protein level. RANTES, IP-10 and IFN β were chosen as 
representative proteins that are regulated by NF-κB and IRF3. 
In order to assess the effect of IL-17RD on the production of these proteins, U373 cell 
lines, stably expressing control and IL-17RD shRNA, were treated with Poly (I:C). 
Supernatants were obtained 24 hours after treatment and used to measure RANTES, IP-10 
and IFN β production by ELISA. In IL-17RD knockdown cells, there were marked increases 
in the production of RANTES (~150%) (Fig 3.6a), IFN β (~50%) (Fig 3.6b) and IP-10 
(~125%)  (Fig 3.6c) in response to Poly (I:C) when compared with the control shRNA cell 
lines. These data corroborate the earlier findings and suggest that IL-17RD may function as 
an endogenous brake in TLR signalling. 
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3.2.4  TLR signalling is enhanced in cells from IL-17RD-deficient mice 
  
The aforementioned knockdown studies indicated IL-17RD as a negative regulator of 
TLR signalling. In order to validate the physiological relevance of such a role, it was 
necessary to generate IL-17RD deficient mice. This was achieved by gene trap technology in 
partnership with the German Genetrap Consortium. The murine il-17rd gene consists of 
thirteen exons. The targeting vector disrupted the il-17rd gene between the first and second 
exons with a β-geomycin resistant gene cassette (Fig 3.7a). IL-17RD knockout pups were 
born in an expected Mendelian ratio and showed no apparent phenotype abnormalities which 
are consistent with previously generated IL-17RD- deficient mice (Abraira et al., 2007). 
BMDM were generated from the IL-17RD mice and used to further explore the regulatory 
role for IL-17RD in TLR signalling by measuring the phosphorylation status of key TLR 
signalling components in response to LPS and Poly I:C. IL-17RD- deficient BMDMs were 
stimulated with either LPS (Fig 3.8) or Poly I:C (Fig. 3.9) over a number of timepoints as 
indicated and the phosphorylation of important downstream effector proteins was examined 
by immunoblotting using specific antibodies. In the wild type macrophages, LPS-induced 
phosphorylation of p65 and IκBα was detectable after 5 minutes and this decreased over time 
but levels of phosphorylated p65 and IκBα were higher and more sustained in IL-17RD –
deficient cells (Fig 3.8). Poly I:C induced phosphorylation of the TBK1 and IRF3 proteins in 
wild type BMDMs but the kinetics were altered in IL-17RD-deficient cells such that the 
Poly(I:C)-induced phosphorylation of TBK1 and IRF3 was apparent at earlier time points 
(Fig 3.9).  
These data validate previous results, demonstrating that IL-17RD is capable of 
inhibiting downstream activation of the main players in TLR signalling pathways, 
emphasising its role as a negative regulator.  
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3.2.5  IL-17RD deficient macrophages exhibit augmented expression of TLR 
responsive genes 
 We next explored the functional consequences of augmented TLR signalling in IL-
17RD knockout cells by measuring the expression of a number of TLR-responsive genes in 
these cells. The representative NF-κB and IRF responsive genes chosen were murine IL-6 
and KC and Type I Interferons respectively. IL-6 is a key NF-κB responsive cytokine. KC is 
the murine homolog of IL-8 and is produced by keratinocytes, monocytes, macrophages and 
endothelial cells. When released by these cells, it functions as a powerful chemoattractant of 
neutrophils, directing these cells to areas of infection to phagocytose invading antigens 
(Baggiolini et al., 1989).  
Wild type and IL-17RD deficient macrophages were treated with the TLR ligands 
LPS (TLR4) , Poly (I:C) (TLR3), Zymosan (TLR2), Flagellin (TLR5) and Pam3Csk4 
(TLR1/2) and a number of key pro-inflammatory cytokines including  IL-17, IL-1β and TNF. 
24 hours post treatment, supernatants were obtained and levels of mIL-6 and KC were 
quantified by ELISA. LPS potently induced mIL-6 in wild type BMDMs but this was further 
augmented in IL-17RD knockout cells (Fig 3.10). Additionally, IL-17RD deficient 
macrophages showed a significant enhancement of mIL-6 production in response to Poly I:C, 
IL-17, Zymosan, Flagellin and Pam3Csk4 relative to their wild type counterparts (Fig 3.10). 
Interestingly, IL-17RD deficiency had no effect on the efficacy of TNF, CpG or IL-1β in 
inducing IL-6. Loss of IL-17RD had similar effects on the expression of KC (Fig 3.11) in that 
IL-17RD knockout cells showed enhanced expression of KC in response to LPS, Poly I:C, 
Pam3Csk4, Flagellin and Zymosan relative to wild type cells. Such an increase in NF-κB 
responsive gene activation support a model in which  IL-17RD acts an endogenous braking 
system for NF-κB  and the induction of NFкB-responsive genes. 
The functional consequence of IL-17RD deficiency on activation of the IRF pathways 
was next examined by measuring the production of Type I Interferons and IFNβ in response 
to Poly I:C in BMDMs from wild type and IL-17RD-deficient mice. IL-17RD deficiency 
potentiated Poly(I:C) induced expression of Type I Interferon as measured by bioassay (Fig 
3.12) and ELISA (3.13). This enhancement in interferon production due to the absence of IL-
17RD confirms that the orphan receptor acts as an endogenous regulator of IRF signalling 
and is capable of targeting the TLR3-TRIF pathway.  
50 
 
3.2.6  IL-17RD deficiency augments TLR induced cytokine mRNA induction 
 To explore if the negative effects of IL-17RD on TLR-responsive genes operated at 
the transcriptional level, it was necessary to verify if induction of TLR responsive cytokine 
mRNA production was elevated in IL-17RD deficient macrophages. The TLR ligands LPS, 
Poly I:C, Zymosan, Flagellin and Pam3Csk4 were chosen as representative ligands. The 
mRNA levels in primary BMDMs were quantified using qPCR analysis. Production of KC 
(Fig 3.14a) and mIL-6 (Fig 3.14b) mRNA, in response to LPS, was enhanced in IL-17RD 
deficient macrophages relative to WT cells. Such augmentation in IL-17RD knockout cells 
was also apparent with respect to mIL-6 (Fig 3.15a) and RANTES (Fig 3.15b) mRNA 
induction in response to Poly I:C. The TLR5 ligand, Flagellin, strongly induced both KC (Fig 
3.16a) and mIL-6 (Fig 3.16b) mRNA expression. Augmented induction of these NF-κB 
responsive genes was displayed in the IL-17RD knockout primary macrophages. Zymosan, a 
component of the fungal cell wall and a powerful TLR 2 agonist, induced both RANTES (Fig 
3.17a) and KC (Fig 3.17b) mRNA in WT cells and this was further increased in IL-17RD-
deficient cells. Furthermore, Pam3Csk4-induced KC mRNA fold induction was potentiated in 
cells lacking IL-17RD (Fig 3.18). Clearly, these results, in conjunction with  earlier data 
above, strongly suggest that IL-17RD functions as a strong negative regulator of TLR 
signalling pathways inhibiting the production of TLR induced expression of inflammatory 
genes such as IL-6, KC and RANTES and type I IFNs.  
3.2.7  Suppression of IL-17RD expression enhances TLR-induced CREB signalling 
 It was subsequently of interest to observe how IL-17RD would affect other 
transcription factors given its strong regulation of the NF-κB and IRF pathways. CREB 
(cAMP response element binding) is a vital transcription factor involved in mediating the 
regulation of gene expression in response to the second messenger, cAMP (Johannesen et al., 
2004). Stimuli that increase cAMP activates cAMP dependent Protein Kinase A (PKA) 
which in turn phosphorylates CREB at Ser-133 increasing its transactivation potential. 
Several TLRs also initiate phosphorylation of CREB leading to enhanced transcription of 
CREB responsive genes such as cyclooxygenase 2 (COX-2) and anti-inflammatory genes 
such as IL-10 (Eliopoulos et al., 2002; Platzer et al., 1999). To this end, it was sought to 
establish the role, if any, IL-17RD had in the CREB activation pathway. Given that a 
prerequisite for CREB activation is Ser-133 phosphorylation, LPS induced CREB 
phosphorylation was characterised in both wild type and IL-17RD deficient BMDMs. Both 
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sets of primary macrophages were stimulated with LPS over various times and the 
phosphorylation of CREB was examined by immunoblotting using a phosphor-Ser-133 
specific antibody. In wild type cells, LPS induced phosphorylation of CREB was detected 
after 5 minutes and was maintained up to an hour (Fig 3.19). However, in IL-17RD deficient 
cells, there was much more pronounced and sustained CREB phosphorylation. Additionally, 
another band, corresponding with the mobility of an approximately 80 kDa protein, was 
detected. This band shares a similar profile as the phospho-CREB, possibly indicating it is a 
modified form of phosphor-CREB. Levels of COX-2 were also examined by immunoblotting 
(Fig 3.19). COX-2 is a key component of the biosynthetic pathway which results in the 
production of prostaglandins. Elevated levels of COX-2 were observed after 60 minutes of 
LPS treatment in the wild type cells. This becomes more pronounced at 4 hours. However, 
there is augmentation in the levels of COX-2 in the IL-17RD deficient macrophages.  
To further examine IL-17RD as a potential effector of a novel regulatory mechanism 
in the CREB pathway, an assessment of the production of the anti-inflammatory IL-10 was 
performed. Produced by monocytes, macrophages and B and T cells, IL-10 
displays pleiotropic effects in immune system regulation and inflammation. It has the ability 
to inhibit the synthesis of pro-inflammatory cytokines such as IFN-γ, TNF and GM-CSF 
made by macrophages and T-reg cells. Also, it is capable of downregulating expression of 
TH1 cytokines, MHC class II antigens, and co-stimulatory molecules on macrophages. 
BMDMs were treated with LPS, Zymosan, Pam3Csk4 and Flagellin. Supernatants were then 
harvested 24 hours post treatment and these were used to measure IL-10 expression by 
ELISA.  In response to each TLR ligand, there is augmented IL-10 production in the IL-
17RD deficient macrophages (Fig 3.20). This suggests an important role of IL-17RD in 
regulating CREB activation and the expression of CREB responsive genes.  
3.2.8  Absence of IL-17RD causes increased TRAF6 ubiquitination in response to TLR 
ligands 
 We next aimed to probe the mechanistic basis to the effects of IL-17RD on the 
various transcription factors and TLR-responsive genes. Since other IL-17 receptors and 
TLRs use TRAF6 as a key signalling intermediate it was interest to probe the effect of Il-
17RD on TRAF6. TRAF6 is a key mediator in NF-κB signalling. It is a ubiquitin E3 ligase 
that can be auto-ubiquitinated and is responsible for the activation of the IKK complex. We 
thus assessed the effect of IL-17RD deficiency on the ubiquitination of TRAF6.  Wild type 
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and IL-17RD deficient macrophages were treated with LPS, over various timepoints (Fig 
3.21). The cell lysates were immunoprecipitated with a specific anti-TRAF6 antibody 
followed by immunoblotting with specific anti-ubiquitin antibodies. Ubiquitination of 
TRAF6 was detected transiently in the wild type macrophages at 10 minutes and 30 minutes 
(Fig 3.21). Such LPS-induced polyubiquitination of TRAF6 was moderately enhanced in the 
IL-17RD deficient cells and such effects on the ubiquitination of TRAF6 are consistent with 
increased LPS-induced activation of NF-κB in the absence of IL-17RD. While this study 
validates the functional data from previous studies, it also furnishes evidence that IL-17RD in 
fact functions either upstream or at the level of TRAF6. Taken together, these studies confirm 
IL-17RD acts as a signalling “brake” in TLR signalling.  
3.2.9  The SEFIR domain of IL-17RD functions similarly to full length IL-17RD 
 Previous work on IL-17RD (unpublished work from the host laboratory), has 
established that IL-17RD interacts with all TIR domain containing adaptor proteins and 
TRAF6 and it inhibits TLR adaptor driven NF-κB luciferase activity in a dose dependent 
fashion. It was decided to establish whether a truncation mutant of IL-17RD containing just 
its SEFIR domain would have the same effects as the wild type. Overexpression of this 
mutant which just contains residues 354-518 (Fig. 3.22a), like full length IL-17RD, showed 
no significant induction of NF-κB activity (Fig 3.22b). The importance of the IL-17RD TIR 
domain and deleted regions for mediating the inhibitory effects of IL-17RD was next 
examined by analysing the effects of the mutants on TIR-adaptor mediated NF-κB activation. 
Increasing amounts of IL-17RD full length and IL-17RD TIR were co-transfected with 
MyD88 and the NF-κB luciferase reporter construct. IL-17RD wild type was employed as a 
positive control to be able to accurately compare the inhibitory effects, if any, of the mutant. 
IL-17RD TIR inhibited, with comparable efficacy, NF-κB activation in a dose dependent 
manner. (Fig 3.24). Such findings strongly implicate an important role for the IL-17RD TIR 
domain in mediating the inhibitory effects of IL-17RD.  
Given that IL-17RD can regulate the ubiquitination of TRAF6, co-
immunoprecipitation studies were performed to analyse whether myc-tagged IL-17RD 
SEFIR could interact with TRAF6. The myc-tagged full length IL-17RD, employed here as a 
positive control, was demonstrated to be capable of interacting with flag-tagged TRAF6. 
Interestingly IL-17RD TIR was also shown to be capable of binding to TRAF6, similar to the 
wild type (Fig 3.23).  
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3.2.10 IL-17RD differentially regulates RIG-I associated NF-κB and IRF activation 
  
Given the profound effects IL-17RD displays on TLR signalling, the regulatory 
effects of IL-17RD on another pathway was subsequently examined. It was interesting to 
observe how IL-17RD would affect the signalling of a non-TLR pathway that also activates 
NF-κB and IRFs. IL-17RD was assessed for its ability to regulate RIG-I signalling. In order 
to explore the physiological relevance of IL-17RD in this pathway, IL-17RD deficient 
BMDMs were infected with Sendai virus (SeV), a potent agonist of RIG-I signalling. SeV is 
a single stranded RNA virus of the Paramyxoviridae family. Primarily infecting mice, it is 
also responsible for morbidity among other rodents such as rats and can even cause mortality 
among swine. RIG-I detects the ssRNA initiating a downstream signalling cascade which is 
responsible for the induction pro-inflammatory and anti-inflammatory cytokines. Initial 
studies focused on comparing cytokine induction in wild type and IL-17RD deficient cells. 
IL-17RD knockout macrophages were infected with SeV and supernatants were harvested 24 
hours after treatment. An interferon bioassay was performed to assess the induction of 
biologically active Type 1 Interferons. SeV induced Type I Interferons in the wild type 
macrophages (Fig 3.25). Intriguingly, diminished Type I Interferon production was observed 
in the knockout macrophages relative to the wild type cells, indicating that IL-17RD could 
play a role mediating RIG-I induced activation of IRFs.  
The supernatants were then used to measure IFN β and mIL-6 production by ELISA. 
Once again, IL-17RD deficient macrophages displayed reduced ability of SeV to induce 
expression of an IRF responsive gene product, IFN β, relative to wild type cells (Fig 3.26). 
Interestingly, when production of mIL-6 was investigated, we saw a statistically significant 
enhanced induction of this NF-κB responsive cytokine in the IL-17RD deficient macrophages 
relative to the wild type cells (Fig 3.27). These differential effects of IL-17RD on RIG-I 
induced activation of NF-κB and IRFs were also observed in the phosphorylation status of 
downstream signalling components. The knockout macrophages displayed elevated 
phosphorylation of the NF-κB subunit p65 relative to the wild type macrophages in response 
to SeV infection (Fig 3.28). This result ties in with the previously reported increase in mIL-6 
production in the absence of IL-17RD. Furthermore, we demonstrated that IL-17RD 
deficiency results in impaired IRF3 phosphorylation in response to SeV which corroborates 
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the reduced Type I Interferon production. These findings confirm that IL-17RD potentially 
mediates the IRF arm of RIG-I signalling while differentially inhibiting NF-κB activation.  
3.2.11 Gene silencing of IL-17RD in human cells enhances IL-17A signalling 
 Given the striking effects that the loss of IL-17RD appears to have on TLR signalling, 
it was intriguing to explore a possible functional role for this protein in other immune 
signalling pathways. As previously outlined, IL-17RD is an orphan receptor of the IL-17 
receptor family, with to date, no known physiological function in IL-17 signalling. In order to 
elucidate a potential role in IL-17 signalling, we studied IL-17A induced NF-κB signalling 
pathways in the absence of IL-17RD. In addition to lentiviral shRNA knockdown studies, 
siRNA studies were also utilised to probe the function of IL-17RD in this system. HEK 293T 
cells were mock transfected or transfected with IL-17RD-specific siRNA or a scrambled 
control siRNA. Subsequently, qPCR was performed to confirm knockdown of IL-17RD 
mRNA. Knockdown of 30-60% was consistently achieved with IL-17RD specific siRNA 
while the scrambled siRNA had no effect (Fig 3.29). The siRNA molecules were then used to 
determine the effects of il-17rd gene silencing on IL-17A induced NF-κB activation. 
HEK293 TLR4 cell lines were transfected with 20nM of IL-17RD specific siRNA or 
scrambled siRNA. 48 hours post treatment; cells were treated with IL-17A over various 
timepoints. IL-17RD siRNA potentiated the activation of downstream components of IL-17 
signalling compared to its scrambled siRNA counterpart. Knockdown of IL-17RD in these 
cells led to enhanced IL-17A-induced phosphorylation of IκB and the MAP Kinases p38 and 
p42/44 (ERK) (Fig 3.30).  
To further validate these studies, the previously generated U373 cell-lines transduced 
with lentivirus to stably express IL-17RD specific shRNA or control shRNA were once again 
utilised. Using the same timepoints used for the siRNA studies, the cells were treated with 
IL-17A. A very similar picture emerged with augmented phosphorylation of p38, ERK, IKK 
and IκB in the absence of IL-17RD relative to the control shRNA (Fig 3.31). To extend these 
studies further to investigate the physiological relevance of IL-17RD, it was necessary to 
probe its regulatory effects on NF-κB responsive cytokines. IL-6 was chosen as a 
representative gene. IL-6 is produced and secreted by epithelial, endothelial and fibroblastic 
cells in response to IL-17. Therefore, complementary experiments were performed where we 
measured levels of IL-6 in response to IL-17 in control and IL-17RD shRNA knockdown 
U373 cells. These cells were treated with IL-17A and 24 hours post treatment, the 
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supernatants were obtained and assessed for IL-6 production by ELISA. Knockdown of 
endogenous IL-17RD expression lead to enhanced IL-6 mRNA (Fig. 3.32) and protein 
production (Fig. 3.33) in response to IL-17A. These data suggest that IL-17RD negatively 
regulates IL-17A signalling pathways and the induction of IL-17 responsive genes.  
3.2.12 IL-17RD deficiency enhances IL-17A induced signalling in primary 
macrophages 
 IL-17A signalling was next examined in cells from IL-17RD deficient mice. IL-17RD 
knockout murine BMDMs were utilised to elucidate a potential regulatory role for IL-17RD 
by measuring IL-6 and KC expression in response to the principal IL-17RA cytokine, IL-
17A. Primary macrophages were treated with IL-17A over a number of timepoints. 
Supernatants were harvested post treatment and levels of IL-6 and KC were measured by 
ELISA. The IL-17A-induced expression of IL-6 expression in wild type cells was further 
enhanced in IL-17RD deficient macrophages (Fig 3.34). Likewise, loss of IL-17RD resulted 
in augmented IL-17-induced expression of KC expression (Fig 3.35). We subsequently 
explored the expression of IL-17A responsive genes at the mRNA level. In addition to IL-6 
and KC, we probed another IL-17 responsive gene, murine MMP9. The matrix 
metalloproteinases (MMPs) are a family of proteases that are important in processes such as 
tissue remodelling, wound healing, tumour invasion and carcinogenesis (Cousens et al., 
2002; Sternlicht et al., 1999; Vu et al., 1998). Aberrant MMP expression is also found in 
autoimmune diseases such as rheumatoid arthritis. IL-17A is a key inducer of MMPs. 
Primary macrophages were treated with IL-17A at 6 and 24 h intervals. Real time PCR was 
carried out to examine the production of IL-6, KC and MMP9 mRNA. IL-17A-induced 
expression of mRNAs encoding IL-6 (Fig 3.36), KC (Fig 3.37) and MMP9 (Fig. 3.38) was 
augmented in the IL-17RD knockout cells. Collectively, these data support a negative 
regulatory role for IL-17RD in IL-17A induced signalling.  
 It was also of interest to observe how IL-17RD would affect the downstream 
signalling components of the IL-17 signalling pathway in IL-17RD deficient macrophages. 
BMDMs were treated with IL-17A over various timepoints and the lysates were subsequently 
immunoblotted for the specific antibodies. An absence of IL-17RD results in increased IL-
17A induced phosphorylation of IκB (Fig 3.39). In terms of MAPK pathways, the most 
notable IL-17RD-mediated response was a decreased activation of p38 MAPK 
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phosphorylation. This surprising finding meant that it was possible that there is some sort of 
differential regulation by murine IL-17RD of the NF-κB and MAPK pathways.  
3.2.13 IL-17RD mediates neutrophil infiltration to the peritoneum 
Given the above differential effects of IL-17RD on IL-17A-signalling we next probed 
the physiological relevance of these effects by evaluating IL-17A-mediated neutrophilia in 
both IL-17RD
+/+
 and IL-17RD
-/-
 mice. Mice were treated with recombinant IL-17A via 
intraperitoneal injection, sacrificed 3 h post-injection and peritoneal cells were collected from 
lavage. Flow cytometric analysis was subsequently performed on the peritoneal exudate cells 
(PECs) to quantitate the neutrophil population (Fig. 3.40a). The administration of IL-17A to 
wild-type mice induced marked neutrophil infiltration into the peritoneum but this was 
dramatically reduced in IL-17RD
-/-
 mice. The greatly diminished neutrophil infiltration in IL-
17RD
-/-
 mice was observed at various times post IL-17A administration (Fig. 3.40b). The 
critical mediatory role for IL-17RD in facilitating neutrophil infiltration was selective for IL-
17A signalling since neutrophil infiltration trigged by the bacterial chemoattractant peptide 
formyl-Met-Leu-Phe was unaffected by loss of IL-17RD (Fig. 3.40c). We next measured the 
expression of IL-6, KC and MIP-2 in PECs isolated from the above treated mice. The in vivo 
administration of IL-17A increased the mRNA levels of all 3 cytokines in PECs from wild-
type mice and in keeping with the earlier cell-based models, the induction of IL-6 and KC 
was further enhanced whilst MIP-2 expression was greatly diminished in PECs from 
similarly-treated IL-17RD
-/-
 mice (Fig. 3.40d). These findings were further corroborated by 
measuring KC and MIP-2 protein levels in lavage fluid from IL-17-treated mice. Again 
administration of IL-17A to wild-type mice caused increased lavage levels of KC and MIP2 
with KC being further enhanced and MIP-2 diminished in similarly-treated IL-17RD
-/-
 mice 
(Fig. 3.40e). Given that IL-17A-induced expression of MIP-2 is greatly suppressed in IL-
17RD
-/-
 mice, coupled to the strong chemoattractant activity of MIP-2 towards neutrophils, 
we investigated if administration of exogenous MIP-2 could overcome the deficiency in IL-
17A-induced neutrophilia that we observed in IL-17RD
-/-
 mice.  We again treated mice with 
IL-17A by intraperitoneal injection, which was followed by intraperitoneal injection of 
recombinant MIP-2 1 h later in order to evaluate if MIP-2 deficiency provided an underlying 
basis to the phenotypic changes on neutrophilia in IL-17RD
-/-
 mice. As before, the 
administration of IL-17A to wild-type mice promoted strong neutrophilia and this was not 
further enhanced by co-administration of MIP-2 indicating that the latter is not a limiting 
factor in wild-type mice (Fig. 3.40f). However, exogenous MIP-2 significantly enhanced 
57 
 
neutrophilia in IL-17A-treated IL-17RD
-/-
 mice consistent with our hypothesis that deficiency 
in MIP-2 expression in IL-17RD-deficient mice may be an important limiting factor 
underlying reduced neutrophilia in these animals (Fig. 3.40f). It is interesting to note that the 
enhanced KC expression in IL-17RD
-/-
 mice failed to compensate for the reduced levels of 
MIP-2. However, a previous study indicated MIP-2 to be a more potent neutrophil 
chemoattractant than KC (Yan et al. 1998). Our findings are consistent with this role for 
MIP-2 being the chief chemoattractant of neutrophils in vivo as the diminished IL-17A-
induced neutrophil infiltration in IL-17RD
-/-
 mice was associated with loss of MIP-2 
expression. 
 
3.2.14 IL-17RD mediates IL-17A-induced pulmonary neutrophilia 
 
The key role of IL-17RD in mediating neutrophil infiltration into the peritoneum in 
response to IL-17A prompted us to examine a more general role for IL-17RD in mediating 
tissue neutrophilia. To investigate this, mice were challenged with IL-17A via intranasal 
injection to elicit pulmonary neutrophilia. Mice were sacrificed after 24 h and cells in the 
bronchoalveloar lavage (BAL) fluid were analyzed (Fig. 3.41a). Consistent with findings 
from intraperitoneal injection, IL-17RD
-/-
 mice had significantly less (p<0.038, Student’s t 
test) lung-infiltrating neutrophils, in response to IL-17A administration, in the BAL fluid 
relative to wild-type animals (Fig. 3.41a). There was no difference in lymphocyte and 
monocyte numbers in BAL fluid between IL-17RD
+/+
 and IL-17RD
-/-
 mice demonstrating a 
specific effect of IL-17RD on neutrophilia. Furthermore, histological analysis of lung tissue 
showed a significant decrease in neutrophil infiltration in IL-17RD
-/-
 mice compared with IL-
17RD
+/+
 mice (Fig. 3.40b). IL-17A-induced expression of IL-6, KC and MIP-2 was also 
measured in lung tissue from the above mice by qPCR (Fig. 3.41c). IL-17A-induced 
expression of KC and IL-6 levels was further augmented in lung tissue from IL-17RD
-/-
 mice 
relative to IL-17RD
+/+
 mice whereas IL-17A-induced MIP-2 expression was greatly reduced 
in lung samples from IL-17RD
-/-
 mice. This is consistent with the observed absence of 
neutrophilia in the lung and reaffirms a critical role for IL-17RD as a mediator of 
neutrophilia. 
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3.2.15 IL-17RD interacts with key IL-17A signalling components and disrupts the 
interaction of TRAF6 and ACT1 
 It was necessary to probe the mechanistic basis for these observed functional effects. 
Given that IL-17RD contains a SEFIR domain, initial studies probed the ability of IL-17RD 
to interact with the SEFIR domain containing adaptor proteins and/or key downstream 
components. Thus, myc-tagged IL-17RD was co-transfected with Flag-tagged ACT1, TRAF5 
and TRAF6. Flag-tagged proteins were immunoprecipitated using an anti-flag antibody and 
immunoprecipitates were probed for the presence of IL-17RD using an anti-myc antibody. 
Interactions were observed with each protein (Fig 3.42). In order to elucidate the possible 
mechanism by which IL-17RD differentially regulates NF-κB and MAPK pathways, the 
interaction of ACT1 and TRAF6 knockdown cells. U373 stably transduced control and IL-
17RD shRNA cells were stimulated as indicated (Fig 3.43). This study demonstrated that the 
interaction of ACT1 with TRAF6 is enhanced in the cells with a lower expression level of IL-
17RD which is consistent with a role for IL-17RD in inhibiting the TRAF6-dependent 
pathway of IL-17 signalling. This suggests that IL-17RD may act as an endogenous braking 
effector mechanism for IL-17A signalling by inhibiting the binding of ACT1 to TRAF6 and 
so blocking the TRAF6 dependent pathway. 
3.2.16 IL-6 production is synergistically enhanced in IL-17RD deficient macrophages in 
response to TLR ligand and IL-17A  
 
Recent insights into IL-17 signalling have shed light into its intricate interplay 
between the innate and adaptive immune systems. IL-17, commonly produced during viral 
and bacterial infection, has the capacity to specifically augment pro-inflammatory responses 
by directly synergising with innate immune signalling pathways (Ryzhakov et al., 2011). As 
such, it was intriguing to explore the physiological effects that IL-17RD exerts on synergism 
between IL-17 signalling and TLR signalling. Murine IL-6 was chosen as a representative 
gene due to it being induced in response to both IL-17 and TLR ligands. Primary 
macrophages were treated with either LPS or Poly I:C with and without IL-17A. The 
supernatants were obtained 24 hours post treatment and the production of mIL-6 was 
measured by ELISA. As expected, mIL-6 levels were raised in the Poly I:C and IL-17A 
treated wild type macrophages compared with the Poly I:C or IL-17 alone treated cells (Fig 
3.44). Additionally, when the IL-17RD deficient macrophages were treated with both ligands, 
59 
 
there was a synergistic enhancement of mIL-6 levels which exceeded that of the wild type 
cells. The same pattern of IL-6 induction was achieved when LPS was substituted for Poly 
I:C (Fig 3.45). These data prove interesting as it displays IL-17RD as a regulator in the 
interplay of immune signalling pathways.  
An overall picture emerges in which IL-17RD can wire various innate immune 
signalling pathways and can differentially regulate sub-pathways that are triggered by innate 
immune receptors.  
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Figure 3.1 Knockdown of endogenous IL-17RD by lentiviral vector-encoded 
shRNA in U373 cell lines 
U373 cells stably transduced with Control or IL-17RD specific-shRNA were cultured 
in the presence of puromycin (10 μg/ml). Total RNA was extracted and cDNA was 
generated using RT. Samples were subsequently assayed by quantitative real-time 
PCR for levels of IL-17RD. Gene expression was calculated relative to the 
housekeeping gene HPRT and analysis was performed using the 2
-ΔΔCT
 method. Data 
represent the mean +/- S.E. of three independent experiments. 
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Figure 3.2 Suppression of endogenous IL-17RD expression enhances LPS 
induced IKK and IκB phosphorylation 
U373 cells stably transduced with Control or IL-17RD-specific shRNA were grown in 
6-well plates for 24 h. Cells were then stimulated with LPS (100 ng/ml) for the 
indicated time periods. Cells extracts were generated and lysates were resolved by 
SDS-PAGE. Western blotting was carried out with anti-phospho-IKK, anti-IKK, anti-
phospho-IκB, anti- IκB and anti-β-actin antibodies. Blots shown are representative of 
two independent experiments. 
  
62 
 
 
 
 
 
Figure 3.3 Suppression of endogenous IL-17RD expression enhances Poly I:C 
induced TBK1 and IRF3 phosphorylation 
U373 cells stably transduced with Control or IL-17RD-specific shRNA were grown in 
6-well plates for 24 h. Cells were then stimulated with Poly I:C (25 μg/ml) for the 
indicated time periods. Cells extracts were generated and lysates were resolved by 
SDS-PAGE. Western blotting was carried out with anti-phospho-TBK1, anti-TBK1, 
anti-phospho-IRF3, anti- IRF3 and anti-β-actin antibodies. Blots shown are 
representative of two independent experiments.  
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Figure 3.4 IL-17RD knockdown augments LPS induced expression of  IL-6 
mRNA  
U373 cells stably transduced with Control or IL-17RD-specific shRNA were grown in 
6-well plates for 24 h. Cells were treated for the indicated time-points with LPS (100 
ng/ml). Total RNA was extracted and cDNA was generated by RT. Samples were 
then assayed by real-time PCR for levels of IL-6. Gene expression was calculated 
relative to the housekeeping gene HPRT and analysis was performed using the 2
-ΔΔCT
 
method. Data represent the mean +/- S.E. of three independent experiments. ** p < 
0.01, paired t-test, LPS stimulated IL-17RD shRNA cells compared with control 
shRNA cells. 
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Figure 3.5 IL-17RD knockdown augments Poly I:C induced expression of  IFNβ 
mRNA 
U373 cells stably transduced with Control or IL-17RD-specific shRNA were grown in 
6-well plates for 24 h. Cells were treated for the indicated time-points with Poly I:C 
(25 μg/ml). Total RNA was extracted and cDNA was generated by RT. Samples were 
then assayed by real-time PCR for levels of IFNβ. Gene expression was calculated 
relative to the housekeeping gene HPRT and analysis was performed using the 2-
ΔΔCT method. Data represent the mean +/- S.E. of three independent experiments. * 
p < 0.05, paired t-test, Poly(I:C) stimulated IL-17RD shRNA cells compared with 
control shRNA cells. 
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Figure 3.6 Knockdown of IL-17RD augments Poly I:C induced expression of 
RANTES, IFN-β and IP-10 
U373 cells stably transduced with Control or IL-17RD-specific shRNA were grown in 
96-well plates for 24 h. Cells were treated for 24 h with Poly I:C (25 μg/ml). 
Supernatants were obtained and analysed for (a) RANTES (b) IFN-β and  (c) IP-10 
production by ELISA. Data represent the mean +/- S.E. of three independent 
experiments. * p <0.05, ** p < 0.01, paired t-test, Poly(I:C) stimulated IL-17RD 
shRNA cells compared with control shRNA cells. 
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Figure 3.7. Generation of IL-17RD-deficient mice. (A) Schematic shows the 
murine il-17rd gene and the genetrap targeting vector, containing a promoter-less 
reporter/selectable marker fusion gene (β-Geo) downstream of a splice acceptor, 
which incorporates into the il-17rd gene after the first exon. Exons are numbered and 
regions targeted by genotyping primers are also indicated. The targeting vector also 
contains frt, f3, lox5171 sites omitted in schematic. (B) Genotyping was performed 
by PCR on genomic DNA from ear punches. Primer 1 and 2 amplify a fragment from 
the WT allele of size 449 bp and from the knockout allele due to insertion of the 
genetrap cassette at a predicted size >7 Kb, however this fragment from the knockout 
allele is too large to amplify. Primer 1 with primer 3 amplifies a fragment spanning 
the genetrap cassette of size 1103 bp and differentiates the IL-17RD knockout allele 
in IL-17RD
+/-
 and IL-17RD
-/-
 mice from IL-17RD
+/+
 mice. To further confirm the 
presence of the genetrap cassette primers 4 and 5 amplify a region of the β-Geo insert 
at a size of 508bp, only found in IL-17RD
+/-
 and IL-17RD
-/-
 mice. (Mellett et al. 
2012)  
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Figure 3.8 IL-17RD deficiency enhances LPS-induced-phosphorylation of IκB 
and p65  
Primary BMDMs from IL-17RD
+/+
 and IL-17RD
-/-
 mice were stimulated with LPS 
(100 ng/ml) as indicated. Cells extracts were generated and lysates were resolved by 
SDS-PAGE. Western blotting was carried out using anti-phospho-p65, anti-p65, anti-
phospho-IκB, anti- IκB, anti-COX-2 and anti-β-actin antibodies. Blots shown are 
representative of three independent experiments. 
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Figure 3.9 IL-17RD deficiency accelerates Poly I:C induced phosphorylation of 
TBK1 and IRF3 
Primary BMDMs from IL-17RD
+/+
 and IL-17RD
-/-
 mice were stimulated with Poly 
I:C as indicated. Cells extracts were generated and lysates were resolved by SDS-
PAGE. Western blotting was carried out with anti-phospho-TBK1, anti-phospho-IRF3 
and anti-β-actin antibodies. Blots shown are representative of three independent 
experiments. 
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Figure 3.10 IL-17RD deficiency augments TLR induced expression of mIL-6 
production 
Primary BMDMs from IL-17RD
+/+
 and IL-17RD
-/-
 mice were stimulated with various 
ligands as indicated. Cells were treated for 24 h. Supernatants were obtained and 
analysed for mIL-6 production by ELISA. Data represent the mean +/- S.E. of three 
independent experiments. * p < 0.05,** p<0.01 paired t-test. 
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Figure 3.11 IL-17RD deficiency augments TLR mediated KC production 
Primary BMDMs from IL-17RD
+/+
 and IL-17RD
-/-
 mice were stimulated with various 
ligands as indicated. Cells were treated for 24 h. Supernatants were obtained and 
analysed for KC production by ELISA. Data represent the mean +/- S.E. of three 
independent experiments. * p < 0.05, ** p < 0.01, ***p < 0.001 paired t-test. 
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Figure 3.12 IL-17RD deficiency enhances Poly I:C induced Type I IFN 
production 
Primary BMDMs from IL-17RD
+/+
 and IL-17RD
-/-
 mice were stimulated with Poly 
I:C. Cells were treated for 24 h. Supernatants were obtained and analysed for Type I 
interferon production using B16-Blue™ IFN-α/β Cells and the detection medium 
QUANTI-BlueTM. Data represent the mean +/- S.E. of three independent experiments. * p 
< 0.05, paired t-test. 
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Figure 3.13 IL-17RD deficiency increased Poly I:C induced IFN-β production 
U373 cells stably transduced with Control or IL-17RD-specific shRNA were grown in 
96-well plates for 24 h. Cells were treated for 24 h with Poly I:C (25 μg/ml). 
Supernatants were obtained and analysed for IFN-β production by ELISA. Data 
represent the mean +/- S.E. of three independent experiments. * p < 0.05, paired t-test, 
Poly(I:C) stimulated IL-17RD shRNA cells compared with control shRNA cells. 
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Figure 3.14 IL-17RD deficiency augments LPS induced expression of KC and 
IL-6 mRNA  
Primary BMDMs from IL-17RD
+/+
 and IL-17RD
-/-
 mice were grown in 6-well plates 
for 24 h. Cells were treated for the indicated time-points with LPS (100 ng/ml). Total 
RNA was extracted and cDNA was generated by RT. Samples were then assayed by 
real-time PCR for levels of KC (a) and IL-6 (b). Gene expression was calculated 
relative to the housekeeping gene HPRT and analysis was performed using the 2
-ΔΔCT
 
method. Data represent the mean +/- S.E. of three independent experiments. * p < 
0.05, paired t-test, LPS stimulated IL-17RD
-/-
 cells compared with IL-17RD
+/+
. 
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Figure 3.15 IL-17RD deficiency augments Poly I:C induced expression of IL-6 
and RANTES mRNA 
Primary BMDMs from IL-17RD
+/+
 and IL-17RD
-/-
 mice were grown in 6-well plates 
for 24 h. Cells were treated for the indicated time-points with Poly I:C (25 μg/ml). 
Total RNA was extracted and cDNA was generated by RT. Samples were then 
assayed by real-time PCR for levels of IL-6 (a) and RANTES (b). Gene expression 
was calculated relative to the housekeeping gene HPRT and analysis was performed 
using the 2
-ΔΔCT
 method. Data represent the mean +/- S.E. of three independent 
experiments. ** p < 0.01, *** p < 0.001 paired t-test, Poly I:C stimulated IL-17RD
-/-
 
cells compared with IL-17RD
+/+
. 
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Figure 3.16 IL-17RD deficiency augments Flagellin induced expression of KC 
and IL-6 mRNA 
Primary BMDMs from IL-17RD
+/+
 and IL-17RD
-/-
 mice were grown in 6-well plates 
for 24 h. Cells were treated for the indicated time-points with Flagellin (100 ng/ml). 
Total RNA was extracted and cDNA was generated by RT. Samples were then 
assayed by real-time PCR for levels of KC (a) and IL-6 (b). Gene expression was 
calculated relative to the housekeeping gene HPRT and analysis was performed using 
the 2
-ΔΔCT
 method. Data represent the mean +/- S.E. of three independent experiments. 
*** p < 0.001, paired t-test, Flagellin stimulated IL-17RD
-/-
 cells compared with IL-
17RD
+/+
. 
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Figure 3.17 IL-17RD deficiency augments Zymosan induced expression of 
RANTES and KC mRNA 
Primary BMDMs from IL-17RD
+/+
 and IL-17RD
-/-
 mice were grown in 6-well plates 
for 24 h. Cells were treated for the indicated time-points with Zymosan (100 ng/ml). 
Total RNA was extracted and cDNA was generated by RT. Samples were then 
assayed by real-time PCR for levels of RANTES (a) and KC (b). Gene expression 
was calculated relative to the housekeeping gene HPRT and analysis was performed 
using the 2
-ΔΔCT
 method. Data represent the mean +/- S.E. of three independent 
experiments. ** p < 0.01, *** p < 0.001 paired t-test, Zymosan stimulated IL-17RD
-/-
 
cells compared with IL-17RD
+/+
. 
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Figure 3.18 IL-17RD deficiency augments Pam3Cysk4 induced expression of KC 
mRNA 
Primary BMDMs from IL-17RD
+/+
 and IL-17RD
-/-
 mice were grown in 6-well plates 
for 24 h. Cells were treated for the indicated time-points with Zymosan (100 ng/ml). 
Total RNA was extracted and cDNA was generated by RT. Samples were then 
assayed by real-time PCR for levels of KC. Gene expression was calculated relative to 
the housekeeping gene HPRT and analysis was performed using the 2
-ΔΔCT
 method. 
Data represent the mean +/- S.E. of three independent experiments. *** p < 0.001, 
paired t-test, Pam3Csk4 stimulated IL-17RD
-/-
 cells compared with IL-17RD
+/+
. 
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Figure 3.19 IL-17RD deficiency enhances LPS induced CREB activation  
Primary BMDMs from IL-17RD
+/+
 and IL-17RD
-/-
 mice were stimulated with LPS 
(100 ng/ml) as indicated. Cells extracts were generated and lysates were resolved by 
SDS-PAGE. Western blotting was carried out probing with anti-phospho-CREB, anti-
COX-2 and anti-β-actin antibodies. Blots shown are representative of three 
independent experiments. 
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Figure 3.20 IL-17RD deficiency augments TLR mediated IL-10 production 
Primary BMDMs from IL-17RD
+/+
 and IL-17RD
-/-
 mice were stimulated with various 
ligands as indicated. Cells were treated for 24 h. Supernatants were obtained and 
analysed for mIL-10 production by ELISA. Data represent the mean +/- S.E. of three 
independent experiments. * p < 0.05, paired t-test. 
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Figure 3.21 IL-17RD deficiency enhances LPS induced ubiquitination of TRAF6 
Primary BMDMs from IL-17RD
+/+
 and IL-17RD
-/-
 mice were stimulated with LPS as 
indicated. Cell lysates were generated and incubated at 95
o
C for 5 min with 0.5% SDS 
to dissociate interacting proteins. Lysates were then immunoprecipitated with an anti-
TRAF6 antibody. Immunoprecipitates and whole cell lysates were then subjected to 
Western immunoblotting with anti-ubiquitin, anti-TRAF6 and anti-β-actin antibodies. 
Blots shown are representative of two independent experiments. 
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Figure 3.22 SEFIR domain of IL-17RD fails to induce NF-κB regulated 
luciferase 
A. Cells were transfected as above and subjected to Western Blotting using anti-myc 
and anti-β-actin antibodies. Blots shown are representative of two independent 
experiments. B. HEK293 TLR4 cells were co-transfected with plasmids encoding NF-
κB-regulated firefly luciferase (80 ng) and constitutively expressed TK Renilla (20 
ng) and with or without plasmids encoding IL-17RD-myc (20, 50, 80 and 100 ng). 
Empty vector pcDNA3.1 was used to normalise the total amount of DNA transfected. 
24 h post transfection cell lysates were generated. Lysates were assayed for firefly and 
Renilla luciferase activity. The data presented are mean +/- S.E.M of triplicate 
determinations from a representative of three independent experiments. 
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Figure 3.23 SEFIR domain interacts with TRAF6 
HEK293 TLR4 cells were co-transfected with plasmids encoding myc-tagged IL-
17RD (2 μg) / IL-17RD TIR and TRAF6-Flag (2 μg). Empty vector pcDNA3.1 was 
used to normalise the total amount of DNA transfected. 24 h post transfection lysates 
were generated and immunoprecipitated with an anti-Flag antibody. 
Immunoprecipitates and whole cell lysates (WCL)s were subjected to Western 
immunoblotting using anti-myc and anti-Flag antibodies. Immunoreactivity was 
visualised using the Odyssey Infrared imaging system. Results shown are 
representative of three independent experiments. 
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Figure 3.24 SEFIR domain shares similar inhibitory effects as the full length 
HEK293 TLR4 cells were co-transfected with plasmids encoding NF-κB-regulated 
firefly luciferase (80 ng) and constitutively expressed TK Renilla (20 ng) and with or 
without plasmids encoding IL-17RD-myc (20, 50, 80 and 100 ng) or IL-17RD-TIR-
myc (20, 50, 80 and 100 ng) and MyD88-flag (50 ng) or Mal-flag (50 ng). Empty 
vector pcDNA3.1 was used to normalise the total amount of DNA transfected. 24 h 
post transfection cell lysates were generated. Lysates were assayed for firefly and 
Renilla luciferase activity. The data presented are mean +/- S.E.M of triplicate 
determinations from a representative of three independent experiments. * p < 0.05, 
paired t-test. 
  
84 
 
 
 
 
 
Figure 3.25 IL-17RD deficiency diminishes SeV induced Type I IFN production 
 
Primary BMDMs from IL-17RD
+/+
 and IL-17RD
-/-
 mice were infected with SeV for 
24 hours. Cells were treated for 24 h. Supernatants were obtained and analysed for 
Type I interferon production by Murine Type I IFNs Sensor Cells (Invivogen). Data 
represent the mean +/- S.E. of three independent experiments. *** p < 0.001, paired t-
test. 
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Figure 3.26 IL-17RD deficiency leads to reduced IFNβ production  
 
Primary BMDMs from IL-17RD
+/+
 and IL-17RD
-/-
 mice were infected with SeV for 
24h. Supernatants were obtained and analysed for IFNβ production by ELISA. Data 
represent the mean +/- S.E. of three independent experiments. ** p < 0.01, paired t-
test. 
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Figure 3.27 IL-17RD deficiency enhances SeV induced IL-6 production.   
 
Primary BMDMs from IL-17RD
+/+
 and IL-17RD
-/-
 mice were infected with SeV for 
24h. Supernatants were obtained and analysed for IL-6 production by ELISA. Data 
represent the mean +/- S.E. of three independent experiments. *** p < 0.001, paired t-
test. 
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Figure 3.28 IL-17RD differentially regulates SeV-induced NF-κB and IRF 
signalling 
 
Primary BMDMs from IL-17RD
+/+
 and IL-17RD
-/-
 mice were infected with SeV as 
indicated. Cells extracts were generated and lysates were resolved by SDS-PAGE. 
Western blotting was carried out by probing with indicated antibodies. Blots shown 
are representative of three independent experiments. 
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Figure 3.29 IL-17RD-specific siRNA suppresses endogenous IL-17RD expression 
in HEK293 cells  
HEK293 TLR3 cells were transfected with IL-17RD specific siRNA or scrambled 
siRNA (20 nM). Total RNA was extracted and cDNA was generated using RT-PCR. 
Samples were subsequently assayed by quantitative real-time PCR for levels of IL-
17RD. Gene expression was calculated relative to the housekeeping gene HPRT and 
analysis was performed using the 2
-ΔΔCT
 method. Data represent the mean +/- S.E. of 
three independent experiments. 
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Figure 3.30 Suppression of endogenous IL-17RD expression enhances IL-17A 
induced signalling  
HEK293 TLR4 cells were transfected with IL-17RD specific siRNA or scrambled 
siRNA (20 nM).  Cells were then stimulated with IL-17A (100 ng/ml) for the 
indicated time periods. Cells extracts were generated and lysates were resolved by 
SDS-PAGE. Western blotting was carried out probing with indicated antibodies. Blots 
shown are representative of two independent experiments. 
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Figure 3.31 IL-17RD shRNA knockdown elevates IL-17A induced signalling 
U373 cells stably transduced with Control or IL-17RD-specific shRNA were grown in 
6-well plates for 24 h. Cells were then stimulated with IL-17A (100 ng/ml) for the 
indicated time periods. Cells extracts were generated and lysates were resolved by 
SDS-PAGE. Western blotting was carried out probing with indicated antibodies. Blots 
shown are representative of two independent experiments. 
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Figure 3.32 IL-17RD knockdown enhances IL-17A induced expression of IL-6  
U373 cells stably transduced with Control or IL-17RD-specific shRNA were grown in 
96-well plates for 24 h. Cells were treated for 24 h with IL-17A (100ng/ml). 
Supernatants were obtained and analysed for IL-6 production by ELISA. Result is 
representative of three independent experiments and the data is mean +/- SD of 
triplicate determinants. 
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Figure 3.33 IL-17RD knockdown augments IL-17A induced IL-6 mRNA 
induction 
U373 cells stably transduced with Control or IL-17RD-specific shRNA were grown in 
6-well plates for 24 h. Cells were treated for the indicated time-points with IL-
17A(100 ng/ml) Total RNA was extracted and cDNA was generated by RT-PCR. 
Samples were then assayed by real-time PCR for levels of IL-6. Gene expression was 
calculated relative to the housekeeping gene HPRT and analysis was performed using 
the 2
-ΔΔCT
 method. Result is representative of three independent experiments and the 
data is mean +/- SD of triplicate determinants. 
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Figure 3.34 IL-17RD deficiency augments IL-17A induced IL-6 production 
Primary BMDMs from IL-17RD
+/+
 and IL-17RD
-/-
 mice were stimulated with IL-17A 
as indicated. Cells were treated for various timepoints as indicated. Supernatants were 
obtained and analysed for IL-6 production by ELISA. Data represent the mean +/- 
S.E. of three independent experiments. ** p < 0.05, paired t-test. 
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Figure 3.35 IL-17RD deficiency augments IL-17A induced KC production 
Primary BMDMs from IL-17RD
+/+
 and IL-17RD
-/-
 mice were stimulated with IL-17A 
as indicated. Cells were treated for various timepoints as indicated. Supernatants were 
obtained and analysed for KC production by ELISA. Data represent the mean +/- S.E. 
of three independent experiments. ** p < 0.01, paired t-test. 
  
95 
 
 
 
 
 
 
Figure 3.36 IL-17RD
 
deficiency increases IL-17A induced IL-6 mRNA 
Primary BMDMs from IL-17RD
+/+
 and IL-17RD
-/-
 mice were stimulated with IL-17A 
as indicated.  Cells were treated for the indicated time-points with IL-17A (100 ng/ml) 
Total RNA was extracted and cDNA was generated by RT-PCR. Samples were then 
assayed by real-time PCR for levels of IL-6. Gene expression was calculated relative 
to the housekeeping gene HPRT and analysis was performed using the 2
-ΔΔCT
 method. 
Result is representative of three independent experiments and the data is mean +/- SD 
of triplicate determinants. 
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Figure 3.37 IL-17RD
 
deficiency increases IL-17A induced KC mRNA 
Primary BMDMs from IL-17RD
+/+
 and IL-17RD
-/-
 mice were stimulated with IL-17A 
as indicated.  Cells were treated for the indicated time-points with IL-17A (100 ng/ml) 
Total RNA was extracted and cDNA was generated by RT-PCR. Samples were then 
assayed by real-time PCR for levels of KC. Gene expression was calculated relative to 
the housekeeping gene HPRT and analysis was performed using the 2
-ΔΔCT
 method. 
Result is representative of three independent experiments and the data is mean +/- SD 
of triplicate determinants. 
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Figure 3.38 IL-17RD
 
deficiency increases IL-17A induced mMMP9 mRNA 
 
Primary BMDMs from IL-17RD
+/+
 and IL-17RD
-/-
 mice were stimulated with IL-17A 
as indicated.  Cells were treated for the indicated time-points with IL-17A (100 ng/ml) 
Total RNA was extracted and cDNA was generated by RT-PCR. Samples were then 
assayed by real-time PCR for levels of mMMP9. Gene expression was calculated 
relative to the housekeeping gene HPRT and analysis was performed using the 2
-ΔΔCT
 
method. Result is representative of three independent experiments and the data is 
mean +/- SD of triplicate determinants. 
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Figure 3.39 IL-17RD differentially regulates IL-17A-induced NF-κB and MAPK 
activation 
 
Primary BMDMs from IL-17RD
+/+
 and IL-17RD
-/-
 mice were stimulated with IL-17A 
(100 ng/ml) as indicated. Cells extracts were generated and lysates were resolved by 
SDS-PAGE. Western blotting was carried out probing with indicated. Blots shown are 
representative of three independent experiments. 
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Figure 3.40 IL-17RD deficiency impairs neutrophil recruitment to the 
peritoneum.(a, b) IL-17A (0.5 µg/mouse) or PBS was administered by 
intraperitoneal injection into IL-17RD
+/+ 
and IL-17RD
-/-
 mice. (a) Representative flow 
cytometry plots of neutrophil infiltration, using CD11b and Ly6G expression as 
markers, 3 h after PBS or IL-17A injection (left panel). Wright’s staining of infiltrate 
from IL-17RD
+/+ 
and IL-17RD
-/-
 mice (right panel). (Scale bar, 10 μm). (b) 
Percentages of neutrophils in peritoneal lavages from mice treated with IL-17A as 
indicated. (c) IL-17A (0.5 µg/mouse), formyl-Met-Leu-Phe (1 µg/mouse) or PBS was 
injected into the peritoneum of IL-17RD
+/+ 
and IL-17RD
-/-
 mice. Data indicates 
percentage (upper panel) and absolute numbers (lower panel) of neutrophils. (d) IL-
17RD
+/+ 
and IL-17RD
-/-
 mice were injected i.p with IL-17A (0.5 µg/mouse). 
Peritoneal cells were collected from mice treated with IL-17A as indicated. IL-6, KC 
and MIP-2 mRNA levels were evaluated by qPCR. (e) ELISA of MIP-2 and KC 
levels from peritoneal lavages from mice treated with IL-17A as indicated. (f) 
Percentages of neutrophils in peritoneal lavages from mice treated with IL-17A or 
PBS for 1 h prior to intraperitoneal injection of murine recombinant MIP-2 (30 ng) for 
2 h. Results are mean +/- SEM (n= 4-7 mice per group) and data are representative of 
three individual experiments (total n= 12-21) (a-c), represent mean +/- SEM of three 
independent experiments (total n=8-9) (d-e) or are mean +/- SEM (total n= 4-9) (f). * 
p<0.05; ** p<0.01; ***p<0.001 (Student’s t test) (Mellett et al. 2012).
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Figure 3.41 IL-17RD regulates IL-17A-induced neutrophil infiltration in lung 
tissue.  
(a, b) IL-17A (0.5 µg/mouse) was introduced intra-nasally into IL-17RD
+/+ 
and IL-
17RD
-/-
 mice. (a) Differential cell count data from cytospin slides depicting 
percentages of neutrophils, lymphocytes and monocytes in BAL at 4 h after IL-17A 
treatment. (b) Representative images of hematoxylin and eosin stained slides from 
lungs taken from IL-17RD
+/+ 
and IL-17RD
-/-
 mice after IL-17A treatment. (Scale bar, 
50 µm). (c) IL-17A (0.5 µg) was introduced intra-nasally for 24 hours and lung tissue 
was retained to measure mRNA levels of IL-6, KC and MIP-2 by qPCR. Results are 
mean +/- SEM (n= 3-4 mice per group) and data are representative of three 
independent experiments (total n= 9-12) (a, b) or are mean +/- SEM (n= 4-6 mice per 
group) (c). * p<0.05; ** p<0.01; ***p<0.001 (Student’s t test). (Mellett et al. 2012). 
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Figure 3.42 IL-17RD interacts with key IL-17A signalling components 
 
HEK293 TLR4 cells were co-transfected with plasmids encoding myc-tagged IL-
17RD (2 μg) and ACT1-Flag (2 μg) or TRAF5-Flag (2 μg) or TRAF6-Flag (2 μg).  
Empty vector pcDNA3.1 was used to normalise the total amount of DNA transfected. 
24 h post transfection lysates were generated and immunoprecipitated with an anti-
Flag antibody. Immunoprecipitates and whole cell lysates (WCLs) were subjected to 
Western immunoblotting using anti-myc and anti-Flag antibodies. Immunoreactivity 
was visualised using the Odyssey Infrared imaging system. Results shown are 
representative of three independent experiments. 
  
IL-17RD 
102 
 
 
 
 
 
 
 
 
Figure 3.43 IL-17RD disrupts the interaction between TRAF6 and ACT1 
 
U373 cells stably transduced with Control or IL-17RD-specific shRNA were grown in 
6-well plates for 24 h. Cells were treated for the indicated time-points with IL-17A 
(100 ng/ml). Lysates were generated and immunoprecipitated with an anti-Flag 
antibody. Immunoprecipitates and whole cell lysates (WCLs) were subjected to 
Western immunoblotting using anti-myc and anti-Flag antibodies. Immunoreactivity 
was visualised using the Odyssey Infrared imaging system. Results shown are 
representative of three independent experiments. 
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Figure 3.44 IL-17RD deficiency results in enhanced IL-17 and Poly I:C 
synergism  
 
Primary BMDMs from IL-17RD
+/+
 and IL-17RD
-/-
 mice were stimulated with IL-17A 
(100 ng/ml) and/or Poly I:C (25 μg/ml) as indicated. Supernatants were obtained and 
analysed for IL-6 production by ELISA. Data represent the mean +/- S.E. of three 
independent experiments. * p < 0.05, paired t-test. 
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Figure 3.45 IL-17RD deficiency results in enhanced IL-17 and LPS synergism  
 
Primary BMDMs from IL-17RD
+/+
 and IL-17RD
-/-
 mice were stimulated with IL-17A 
(100 ng/ml) and/or LPS (100 ng/ml) as indicated. Supernatants were obtained and 
analysed for IL-6 production by ELISA. Data represent the mean +/- S.E. of three 
independent experiments. * p < 0.05, paired t-test. 
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4.1 Discussion 
 
The initial aim of this body of work was to test whether IL-17RD could affect innate 
immune signalling pathways as a result of its SEFIR domain which shares structural 
similarity to the TIR domain of TLR signalling. Most TIR domain containing adaptor 
proteins induce pro-inflammatory signals by activating NF-κB. Some adaptor proteins 
including MyD88 and TRIF also have the capacity to induce IRF signalling. On the other 
hand, several TIR domain containing proteins are inhibitors of immune signalling. ST2, a 
TIR domain containing protein, can interact with MyD88 and Mal to inhibit TLR2, TLR4 and 
TLR9 signalling (Brint et al., 2004) while SIGGIR obstructs TLR4 and TLR9 and IL-1 
signalling (Wald et al., 2003).  
We began by looking at the effect of IL-17RD on pathways regulated by TLRs. 
Unlike SARM, for example, IL-17RD was demonstrated to inhibit each of the adaptor 
proteins from activating NF-κB. IL-17RD inhibited TLR3 and TLR4 ligands from activating 
NF-κB. In terms of TLR signalling, IL-17RD also inhibited Flagellin, Zymosan and 
Pam3Csk4 mediated activation of NF-κB. The inhibition of downstream signalling proteins 
such as TRAF6, IκB and p65 indicates that IL-17RD could target multiple components. This 
might explain why IL-17RD has the ability to interfere with non-TLR pathways. IL-17 and 
RIG-I share common components with the TLR signalling pathways such as TRAF6 and 
IKKs, all of which are vulnerable to the regulatory effects of IL-17RD. As well as targeting 
NF-κB signalling, IL-17RD disrupts activation of the IRFs by TRIF. The IRFs play a 
fundamental role in Type I interferon activation. 
The subcellular location of IL-17RD may play an important role in its regulatory 
effects. Several reports have demonstrated that IL-17RD is dispersed throughout the cell. It 
translocates to the Golgi in the spatial regulation of ERK signalling (Torii et al 2004). It’s 
been demonstrated to be primarily localised to the cytoplasm and to intracellular vesicles but 
relocates to the plasma membrane upon FGF treatment (Ren et al. 2006). Due to Ras 
signalling consisting of endocytotic recycling, it was proposed that IL-17RD targeted Ras 
signalling at both the plasma membrane and the endocytic vesicles (Roy et al. 2002). 
Crucially, IL-17RD’s distribution at the plasma membrane and the endosomal vesicles is 
consistent with the localisation of the TLRs. Recently, endosomal IL-17RD has been shown 
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to inhibit IL-1 and TNF signalling (Fuchs et al. 2012). In IL-17RD expressing cells, both 
IκBα and IL-17RD regulate cytoplasmic sequestration of NF-κB. Upon IL-1 stimulation, IκB 
is swiftly degraded while IL-17RD remains bound to large amounts of NF-κB and thereby 
impedes NF-κB nuclear translocation. IκB and IL-17RD, both targets of NF-κB, function 
cooperatively to terminate the NF-κB response. Nascent IκBα enters the nucleus and exports 
NF-κB to the cytoplasm while newly synthesized IL-17RD sequesters the exported IκBα/NF-
κB complex (Fuchs et al. 2012). 
 Previous studies in the laboratory consisted of overexpression of IL-17RD and 
analysis of its functional effects.  However, overexpression of signalling proteins generates 
the potential for artefacts. Consequently, siRNA and shRNA approaches were taken to 
specifically look at the functional consequences of knocking down endogenous IL-17RD. 
The results in this body of work, generated with siRNA and shRNA technology, confirmed 
what was previously demonstrated in over expression studies. NF-κB activation was 
enhanced in knockdown cells. The physiological relevance of IL-17RD of the inhibitory 
effects of IL-17RD was also shown by the generation of IL-17RD deficient mice. In the 
absence of normal endogenous IL-17RD, cytokine induction was enhanced in response to IL-
17A and TLR ligands. IL-17RD dampens down the inflammatory response by decreasing the 
production of chemokines such as IL-8 (and its murine homolog, KC), RANTES and IL-6. 
These findings strongly indicate that IL-17RD is an important endogenous regulator of 
inflammatory signals. The reason why an FGF antagonist has such an impact on innate 
immune signalling pathways is unclear. IL-17RD is important in regulating early 
developmental signalling during embryogenesis and also been linked with nervous system 
development (Tsang et al. 2002; Abraira et al. 2007). Interestingly, TLRs are intricately 
involved in early development; in fact, Drosophila Toll was initially demonstrated to be 
responsible for dorsoventral patterning in developing larvae (Anderson et al. 1985). As a 
result, IL-17RD may have evolved along with the TLRs to become an immune signalling 
regulator.  
 Mutational analysis was carried out to probe a possible mechanism by which IL-
17RD exerts its inhibitory effects on TLR mediated NF-κB and IRF activation. The TIR 
domain has been shown to be an important mediator of IL-17RD’s inhibitory effects given 
how it seems to be sufficient to maintain the level of inhibition achieved by the full length IL-
17RD. In addition, the interaction between IL-17RD and TRAF6 is maintained when 
everything except the SEFIR domain is lost implying that once again, the SEFIR domain may 
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be sufficient to enable TRAF6 interact with IL-17RD. However, while the SEFIR domain of 
IL-17RD is important for the function of IL-17RD in TLR signalling, IL-17RD is also able to 
affect non-TLR pathways. Possession of both TRAF6 and TRAF5 binding site may confer on 
IL-17RD the ability to disrupt pathways that encompass these downstream effector proteins.  
Based on structural similarity the IL-17 receptor family is constituted by 5 members 
(Gaffen 2009). To date, direct functional data has demonstrated a role for only 4 of the IL-17 
receptors (A, B, C and E) in IL-17 signalling. Despite sharing structural features with these 
other family members, IL-17RD remains an orphan receptor with no available data indicating 
a physiologically relevant role for IL-17RD in IL-17 biology. We now report for the first 
time, a regulatory role for IL-17RD in IL-17A-induced neutrophilia and activation of MAPK 
and NF-κB signalling pathways.  
Previous findings have demonstrated that IL-17RA, -B, -C and –E, but not IL-17RD, 
are upregulated upon IL-17A stimulation (Zhang et al 2010). Instead basal IL-17RD 
expression is relatively high compared with IL-17RA and this is consistent with our proposed 
role for the orphan receptor acting as a basal “braking system” that needs to be relieved by 
IL-17A stimulation in order to manifest activation of NF-κB and induction of pro-
inflammatory cytokines and chemokines. Importantly, IL-17RD appears to act to 
differentially regulate various IL-17-responsive genes. Whilst IL-17RD negatively regulates 
IL-17-induced expression of pro-inflammatory genes such as IL-6 and KC, it also fulfills a 
key mediatory role in facilitating IL-17-induced expression of other pro-inflammatory 
proteins like MIP-2. Indeed in an inflammatory context, the latter positive role of IL-17RD in 
IL-17 signalling, appears to be the dominant one at least in the context of IL-17A-induced 
neutrophilia, since in the present study IL-17RD-deficient mice show greatly diminished 
neutrophil recruitment in tissues challenged with IL-17A. We also provide a mechanistic 
basis to the differential effects of IL-17RD on IL-17-responsive genes. We propose that IL-
17RD negatively regulates NF-κB by sequestering Act1 and preventing its interaction with 
IL-17RA and TRAF6 thus inhibiting ubiquitination of the latter and downstream activation of 
NF-κB and induction of genes such as IL-6 and KC. Intriguingly, IL-17RD also appears to 
have a contrasting mediatory role in IL-17A-induced phosphorylation of p38 MAPK and 
induction of MIP-2. The latter is especially important in terms of a critical physiological role 
for IL-17A in mediating tissue neutrophilia. Such findings also emphasize the complexity of 
the IL-17A signalling pathway. To date IL-17 signal transduction has been divided into 
TRAF6-dependent and TRAF6-independent pathways, the former assumed to trigger 
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activation of NF-κB and MAPKs while the latter regulates mRNA stability. However, the 
present study clearly shows that IL-17RD can differentially regulate both the NF-κB and p38 
MAPK pathways.  
In addition to these findings, data which could prove particularly therapeutically 
informative are results which demonstrated that loss of IL-17RD leads to synergistic 
augmentation of pro-inflammatory cytokines in response to TLR ligands and IL-17. This may 
be physiologically relevant given the role of IL-17, PAMPs and DAMPs in a variety of 
chronic inflammatory diseases, most notably Rheumatoid Arthritis. IL-17, for example, has 
been shown to enhance the production of inflammation inducing cytokines in synovial fluid 
as well as the destruction of cartilage tissue (Kuligowska and Odrowaz-Sypniewska 2004). A 
mechanism, by which attenuation of synergistic induction of these cytokines by DAMPs and 
IL-17, could prove particularly useful as a potential target for therapies.  
 The effect of IL-17RD on RIG-I signaling proved intriguing in that it differentially 
regulated the activation of NF-κB and IRF3. While elevated levels of IL-6 were demonstrated 
in the absence of IL-17RD in response to SeV infection, Type I interferon production was 
diminished. This identifies a possibly divergence in mechanism between the two arms of 
signaling and could prove useful in the delineation of the mechanism of IL-17RD function in 
other pathways. Common elements in the TLR activation of NF-κB and IRF pathways which 
are targeted by IL-17RD may be absent or have an opposite function in the IRF wing of RIG-
I signaling which would account for the differential regulation.   
IL-17RD is a multifunctional protein with a large variety of roles in negatively 
regulating growth factor signaling, in early development, in cell cycling and also, now, in the 
immune system. Although IL-17RD has an important role in FGF signaling, particularly in 
early development, IL-17RD deficient mice proved to be healthy and viable with no obvious 
clinical features (Lin et al. 2005). As a result, these mice proved to be an essential tool in the 
study of IL-17RD functioning in innate immune signaling pathways in order to confirm the 
physiologically relevant nature of the knockdown and overexpression studies. This is despite 
the fact that it has been reported that IL-17RD deficiency in humans has been implicated in a 
number of cancers (Zisman-Rozen et al. 2007). IL-17RD was highly expressed in normal 
epithelial cells but its expression was abrogated in the equivalent carcinomas. As of yet, there 
has been no signs of abnormal tumour growth in the IL-17RD
-/-
 mice (Mellett et al. 2012). Of 
interest to the immune functions of IL-17RD are the elevated expression levels of IL-17RD in 
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epithelial cells. Epithelial cells have the ability to show tolerance to foreign microbes and IL-
17RD could reasonably have a function in this process.  
Given the versatile nature of IL-17RD and the fact that it impacts upon a variety of 
pathways, this may make IL-17RD a viable candidate as a potential therapeutic target. What 
could prove most insightful is discovering the ligand for IL-17RD which may potentially 
have a therapeutic application in limiting tumour formation and also be of value 
therapeutically in staving off unwanted immune mediated disease. The use of agonistic or 
antagonistic antibodies for IL-17RD could be one way in which the therapeutic value of IL-
17RD could be exploited. For example, there has been much work into the use of anti-TNF 
antibodies in autoimmune disease particularly in rheumatoid arthritis (Feldmann and Maini 
2003). In fact, by the end of the last decade, anti-TNF therapies were worth upwards of $22 
billion (Pappas et al. 2009).   There are a host of chronic inflammatory disorders which could 
be tackled by curbing dysregulated inflammatory cytokine induction and knowledge of how 
the inflammatory signaling is regulated could lead to treatments for the millions of sufferers. 
Characterising negative regulators like IL-17RD could provide novel treatment targets or at 
least inform us in more detail of how the inflammatory response operates on a basic level. 
As more information is reported, it is becoming apparent that there is a network of 
crosstalk between inflammatory pathways. Originally, studies of these pathways focused on 
identifying the components of these pathways which led to transcription factor activation. 
More recently there has been an increasing focus on negative regulators of these pathways 
since this allows for homeostasis in innate immune signalling (Germain 2012). These 
regulators, rather than having an all or nothing effect, in fact function together at different 
strata in the signalling cascades to tweak the inflammatory response. These diverse, stratified 
mechanisms include anatomical barriers like the skin, innate wound responses like anti-
thrombin III, PAMP sequestration mediators like soluble TLR2, PAMP signalling inhibitors 
like A20 and transcription factors such as Bcl-6 (Murray and Smale 2012).  This thesis, by 
characterizing the physiological relevance of IL-17RD in innate immune signaling pathways, 
proposes that we now add IL-17RD to the growing list of regulators which function to keep 
the immune system in check and advances it as potential target for immune mediated disease 
therapies. 
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